Washington University in St. Louis

Washington University Open Scholarship
All Theses and Dissertations (ETDs)
January 2009

Discovery Of Inactive E* Conformations In Thrombin And Other
Vitamin K- Dependent Clotting Proteases
Alaji Bah
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/etd

Recommended Citation
Bah, Alaji, "Discovery Of Inactive E* Conformations In Thrombin And Other Vitamin K- Dependent Clotting
Proteases" (2009). All Theses and Dissertations (ETDs). 28.
https://openscholarship.wustl.edu/etd/28

This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has
been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington
University Open Scholarship. For more information, please contact digital@wumail.wustl.edu.

WASHINGTON UNIVSERSITY IN ST. LOUIS
DEPARTMENT OF BIOCHEMISTRY & MOLECULAR BIOPHYSICS

Dissertation Committee:
Enrico Di Cera (Supervisor)
Carl Frieden (Chair)
Tom Ellenberger
Roberto Galletto
F. Scott Mathews
Douglas Tollefsen

Discovery Of Inactive E* Conformations In Thrombin And Other Vitamin K- Dependent
Clotting Proteases

by

Alaji Bah
A dissertation presented to the Graduate School of Arts and Sciences
of Washington University in partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

December, 2009
Saint Louis, Missouri. USA

i

ABSTRACT OF THE DISSERTATION

Discovery Of Inactive E* Conformations In Thrombin And Other Vitamin K- Dependent
Clotting Proteases

by

Alaji Bah

Doctor of Philosophy in Biology and Biomedical Sciences (Biochemistry)

Washington University in St. Louis, 2009

Professor Enrico Di Cera, Supervisor

Serine proteases of the chymotrypsin family play important roles in the regulation and
function of numerous biological processes including digestion, blood coagulation,
fibrinolysis, development, fertilization, apoptosis and immunity. For many of these
proteases, activity unfolds when a zymogen is activated by limited proteolysis and the
associated conformational changes result in the formation of a proper active site and
oxyanion hole, both of which are required for efficient hydrolysis of peptide bonds. The
transition from zymogen to active enzyme, E, thus provides critical temporal and spatial
regulatory mechanism of protease function.
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Catalytic activity of serine proteases belonging to Vitamin K-dependent clotting factors is
significantly affected by Na+ through an allosteric mechanism. Over the past 30 years,
structural and biochemical studies revealed that Na+ enhances the enzymatic properties of
these proteases from a low activity, E, to a high activity (E:Na+) conformation. However,
investigation of the effects of Na+ on these proteases has mainly focused on the
thermodynamics of interaction and the resulting catalytic enhancement, with little
emphasis on characterizing the kinetics of Na+ binding. In deed, the kinetic mechanism of
Na+ binding to many Na+-activated enzymes remain for the most part unexplored due to
lack of convenient probes to monitor the interaction or the difficulty of resolving rate
constants for reactions that likely occur on a very fast time scale. My thesis project aims
to fill this gap in the investigation of Na+-activated proteases by elucidating the kinetic
mechanism of Na+ binding to vitamin K-dependent clotting factors.

While studying the kinetics of Na+ binding to human α-thrombin, we observed a biphasic
mechanism of binding whose analysis led to the discovery that in the absence of Na+, the
enzyme exists in dynamic equilibrium between two conformations, E* and E. Structural
and kinetic studies indicate that E is the active form of the enzyme responsible for its
catalytic properties while E* is an inactive conformation that features a collapsed active
site cleft, a disrupted oxyanion hole and an abrogated Na+ binding site. E* is not unique
to α-thrombin, however, as we have observed a similar E* to E transition in meizothrombin-des F1, factor IXa, factor Xa and activated protein C.
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Discovery of E* to E transition embedded in these trypsin-like enzymes is novel, and the
observation of E*-like features in structures of other serine proteases reveal a level of
unprecedented conformational plasticity present in the chymotrypsin fold. The interconversion between E* and E has mechanistic significance on how these proteases
function in vivo. Based on the physiological role of each protease, catalytic activity can
be regulated by properly setting the E*–E equilibrium, favoring E* or E depending on
whether that protease requires low or high catalytic activity for its in vivo function. More
importantly, stabilization of E* through mutagenesis can provide a low activity enzyme
incapable of interacting with substrate or binding inhibitor until an appropriate cofactor
binds and unleashes its full catalytic activity.

Using α-thrombin, a key enzyme of blood coagulation as a model system, we
demonstrated how each conformation could be stabilized through rational protein
engineering using site-directed mutagenesis. Stabilization of its E* form will turn αthrombin into an effective anticoagulant agent that can be utilized for in vivo therapeutic
purposes. In fact, α-thrombin mutants, E217K and W215A/E217A that show
anticoagulant and antithrombotic effects in non-human primates both exhibit some
structural features of E* like partial collapse of the 215-217 β-strand and disruption of
the oxyanion hole. Thus stabilization of E* through mutagenesis or binding of a small
molecule can provide an elegant regulatory control that can fine tune specificity along a
particular pathway. In addition, discovery of E* in Na+-activated clotting proteases
expands our understanding of allostery in monomeric enzymes in general and in
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particular explains why the activity of some thrombin mutants is orders of magnitude
lower than the activity of the wild-type in the absence of Na+.

Findings from this thesis project reveal a fundamental property of structure-function
regulation in the vitamin K dependent clotting enzymes and thus set the stage for further
investigation of inactive conformations in other serine proteases of the chymotrypsin
family. Whether the presence of E* is a universal property of all serine proteases will
await future studies.
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CHAPTER I
Introduction

1

SERINE PROTEASES
Serine proteases, which derive their name from the nucleophilic serine residue in the
enzyme active site, make up the largest group of proteolytic enzymes, forming more than
a third of all known proteases (1-3). Serine proteases are present in every kingdom of
cellular life, and are grouped into clans and families based on their catalytic mechanism
and common ancestry respectively (4). They play critical roles in the function and
regulation of many biological processes including digestion, coagulation, fibrinolysis,
and complement activation as well as cell proliferation, activation and differentiation (3).
Several excellent reviews are available in the literature that describes in depth the
diversity, structure and functions of serine proteases (1, 2, 5-8). In what follows, I will
give a brief overview of that aspect of serine proteases that is relevant to this thesis
project.

The largest group of serine proteases belongs to the Clan PA, family S1 peptidases which
are further divided into S1A and S1B subfamilies. S1A proteases are extracellular and are
mostly found in eukaryotic organisms while S1B proteases participate in protein turnover
in all organisms (1, 5). Although they are phylogenitically distinct, S1A and S1B
proteases contain the same chymotrypsin fold and utilize the canonical catalytic triad of
Ser195, His57 and Asp102 (chymotrypsin numbering used throughout) in hydrolyzing a
peptide bond (Figure 1.1) (9). The occurrence of this triad in identical spatial
configuration in trypsins, subtilisin, prolyl oligopeptidase and ClpP peptidases is an
indication of its success as efficient catalytic machinery (1).
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Peptidase activity occurs via two tetrahedral intermediates and is divided into three main
stages: (i) formation of an enzyme-substrate Michaelis-Menten complex (ii) acylation
and(iii) de-acylation steps (Figure 1.2). Even though the majority of serine proteases are
endopeptidases that hydrolyze peptide bonds within polypeptide chains, there are some
exopeptidases that cleave residues from either the N- or C-terminal of substrates. Many
S1 peptidases usually require proteolytic activation from a zymogen precursor. Cleaving
between residues 15 and 16 results in the formation of ion pair between the nascent Nterminus and Asp194, which induces a conformational change that stabilizes an accessible
active site architecture and proper formation of an oxyanion hole (10-12) (Figure 1.1).

Asp 102

His 57

Ser 195

Asp 189

Figure 1.1 Cartoon representation of the 3-D structure of a typical serine protease of the S1 family of
proteases. Residues of the catalytic triad located between the two β-barrel (yellow), ion-pair (blue dashes)
between residues 16 and 194 & Asp189 at the bottom of primary specificity pocket are all shown in stick
model. PDB Code (2PTN).
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Figure 1.2 Catalytic mechanism of serine protease peptide bond hydrolysis.
With the aid of His57 acting as a general base, the hydroxyl group of the catalytic ser195 attacks the carbonyl
group of the amide substrate. This leads to the formation of a tetrahedral anion intermediate, which is
stabilized by the oxyanion hole, a net positively charge pocket formed by the N atoms of Ser195 and Gly193.
Collapse of the tetrahedral intermediate results in the formation of an acyl-enzyme complex and
stabilization of the new N-terminus by His57. Finally, a water molecule displaces the free N-terminus
product and then attacks the acyl-enzyme intermediate to form another tetrahedral intermediate. The
collapse of this intermediate releases the new C-terminus of the product (2).

In the chymotrypsin fold, residues responsible for catalysis and regulation are distributed
across the entire protein. The catalytic triad is strategically located at the interface of two
six-stranded β-barrels with His57 and Asp102 residing at the N-terminal β-barrel while
Ser195 and the oxyanion hole are located in the C-terminal β-barrel (13) (Figure 1.1). The
active site face is defined by surface exposed loops that mediate substrate specificity and
allostery through interaction with substrates, cations or macromolecular cofactors (1). As
a result, within the same fold for instance, trypsin is optimized to cleave after Arg/Lys
residues while chymotrypsin prefer aromatic side chains.

The molecular origin of the difference in substrate specificity within S1 proteases is not
fully understood (3). The architecture of the primary specificity pocket partly determines
their corresponding specificity since its engineering is necessary but not sufficient for
converting one protease into another. However, extensive additional mutations at loops
not directly in contact with substrate are also required to generate substrate specificity
conversion (14). Nonetheless, the resulting catalytic activity of these engineered mutants
are poor relative to the wild type enzyme. For example, the swapping of chymotrypsin
5

into trypsin or trypsin into elastase is never fully realized (15, 16). These results
demonstrate our current lack of understanding of the determinants of substrate specificity
in S1 serine proteases. The linkage between structure and function underlying the
mechanism of protease specificity is missing a key element. The considerable
conformational plasticity and the allosteric pathways embedded in the chymotrypsin fold
may be the missing link (3).

THE BLOOD COAGULATION CASCADE
Serine proteases of the chymotrypsin family play important roles in the blood coagulation
cascade. Blood coagulation, a key component of homeostasis, evolved as a specialization
of the complement system and immune response (17). The coagulation cascade involves
several proteins that act together following vascular injury to generate a clot that prevents
a severe loss of body fluids and/or pathogenic invasion (18). The initiation and
termination of the clotting process is timely and localized, otherwise uncontrolled clot
formation will result in the occlusion of blood vessels and thrombosis, which can lead to
cardiovascular diseases such as strokes and heart attacks.

Thus, a tightly-regulated

coagulation cascade is essential for survival to prevent excessive bleeding or widespread
clot deposits (18).

The blood coagulation cascade can be initiated through two pathways known as the
intrinsic (contact) and extrinsic (tissue factor) pathways (Figure 1.3) (18). Each pathway
consists of a series of zymogen activation steps where a newly activated enzyme
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catalyzes the activation of the next zymogen in the series until prothrombin is converted
to thrombin. Thrombin then cleaves fibrinogen to form an insoluble clot that anchors the
activated platelets to the site of lesion to initiate the process of wound repair. In addition,
thrombin stabilizes the clot by generating the transglutaminase, FXIIIa, that crosslinks
the nascent clot, and down regulates the fibrinolytic system by activating Thrombinactivatable fibrinolysis inhibitor (TAFI). TAFIa removes C-terminal lysines and arginine
residues from fibrin, hence reducing the ability of fibrin to initiate the fibrinolyic
response(17).

Laboratory and clinical data have shown that the primary route of initiating the
coagulation cascade after vascular injury is the extrinsic pathway (18). This pathway is
composed of three procoagulant vitamin K-dependent enzyme complexes and one
anticoagulant enzyme complex (Figure 1.3). Each haemostatic complex consists of a
vitamin K dependent clotting enzyme and a macromolecular cofactor, assembled in a
Ca2+ dependent manner on a phospholipids membrane of activated or damaged cells. The
central event of the coagulation cascade is the formation of thrombin, and can be divided
into three distinct phases (initiation, propagation and termination).

Thrombin generation begins by exposure of tissue factor that forms a complex with factor
VIIa and results in the generation of small quantities of factors IXa and Xa (19, 20). This
small concentration of Xa produces minute amounts of thrombin (initial phase) that can
activate factor XI and cofactors VIII and V. During the propagation phase, the
procoagulant complexes are assembled, and they enhance the generation of FXa and
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thrombin in the tenase (IXa, VIIIa, Ca2+, phospholipids, X) and prothrombinase (Xa, Va,
Ca2+, phospholipids, prothrombin) complexes by ~5 orders of magnitude relative to their
free enzymes.

The termination phases involves the coordination of stoichiometric and dynamic
inhibitors that down regulate the explosive generation of thrombin to halt the progression
of the coagulation cascade. Although antithrombin III (AT-III) and the tissue factor
pathway inhibitor (TFPI) are the principal stoichiometric inhibitors, heparin cofactor II,
α2-macroglobulin, α1-antitrypsin, activated protein C inhibitor are essential inhibitors
that contribute in regulating the coagulation cascade as well (21, 22). AT-III is a potent
neutralizer of all the procoagulant enzymes while TFPI shuts down the generation of
Factors IXa and Xa by effectively inhibiting the tissue factor-VIIa-Xa complex (Figure
1.3).

The dynamic inhibitory system is composed of the thrombin-thrombomodulin-protein C
system (23). Binding of thrombin onto thrombomodulin, a receptor constitutively
expressed on the surface of the endothelium, prevents the cleavage of fibrinogen and the
activation of PARs, but enhances the activation of protein C over a 1000-fold. Activated
protein C binds and cleaves cofactors VIIIa and Va thereby inactivating the tenase and
prothrombinase complexes respectively. As a result, the exponential amplification of αthrombin generation is down regulated.
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In addition to its roles in the coagulation cascade, other important effects are triggered by
thrombin upon cleavage of protease-activated receptors (PARs), which are members of
the G-protein-coupled receptor super family. Four PARs have been cloned and they all
share similar mechanism of activation (24). Thrombin and other proteases, derived from
the circulatory and inflammatory cells, cleave at a specific site within the extracellular Nterminus to expose a new N-terminal tethered ligand domain, which binds to and
activates the cleaved receptors (25). Thrombin activates PAR1 (26), PAR3 (27, 28) and
PAR4 (29-31) through this mechanism and elicit several cellular responses.
Consequently, thrombin is a potent mitogen that affects the physiology of many cell types
including smooth muscles, macrophages and endothelial cells. In addition, thrombin is by
far the most potent platelet activator. PAR1 is responsible for platelet activation in
humans at low thrombin concentrations and its action is reinforced by PAR4 at higher
concentrations of the enzyme (25). Activation of PAR1 and PAR4 triggers platelet
activation and aggregation and unfolds the prothombotic role of thrombin in the blood.

9

Figure 1.3 The Blood Coagulation Cascade. Shown are the intrinsic (contact) and extrinsic (tissue factor)
pathways of initiation thrombin generation. Zymogens (squares), procoagulant enzymes (blue ovals),
cofactors (red ovals), anticoagulant enzymes (green ovals), platelets (red diamonds) and inhibitors (white
pentagons) (17, 18, 24).
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Na+ ACTIVATION & VITAMIN K-DEPENDENT CLOTTING FACTORS
Metal ions play a key role in serine proteases of the vitamin K dependence clotting
factors as well as in many other enzyme-catalyzed biological processes (32-34). The first
observation of monovalent cation (M+) activation of enzymes was made by Boyer et. al.
(35) when they discovered that K+ was absolutely required by pyruvate kinase for
catalytic activity (36). Later, Monod demonstrated Na+-dependent catalytic rate
enhancement in β-galactosidase (37) and thereafter, the activities of many enzymes were
observed to be modulated by M+ (38). Due to the tight control of the [M+] in vivo, M+ are
not regulators of enzyme activity. They function by lowering the energy barriers in the
ground or transition states, hence affecting substrate binding or catalysis (39).

A recent classification of M+-activated enzymes groups them according to the selectivity
of the effect and the mechanism of activation, as established from kinetic and structural
analysis respectively (40). The mechanism of activation can be can be either cofactor-like
or allosteric. In the former case known as type I, M+ is absolutely required for catalysis
because it anchors the substrate to the enzyme’s active site. However, in the later case
called Type II, M+ enhances enzyme activity through conformational changes induced
upon binding to a distant site where M+ makes no direct interaction with the substrate. In
this case, that is most relevant to the vitamin K- dependent family of clotting enzymes (1,
41), the M+ acts as an allosteric effector and is not absolutely required for catalysis since
the enzyme is still active in the absence of M+.
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Na+ influences the activity of all vitamin K -dependent clotting enzymes. Orthner and
Kosow were the first to show that factor Xa (42) and thrombin (43) are optimally active
in the presence of Na+ while Steiner and Castellino made a similar observation in
activated protein C (44-47). Since then, it has been demonstrated that Na+ had a
significant influence on the activity of factor VIIa (48, 49), factor IXa (50) and
meizothrombin-desF1 (51, 52).

Wells and Di Cera first established that the Na+ activation of human thrombin is specific
and allosteric, and involves the transition of the enzyme between two active forms (53)
leading to an increase in kcat and a decrease in Km. These forms are E with low activity
and E: Na+ with high activity, originally defined as the slow and fast forms respectively
(53). Because the Kd for Na+ binding to thrombin is 110 mM at 37oC, the physiological
concentration of NaCl of 140 mM is not enough to saturate thrombin. As a result, both
the E and E: Na+ forms of thrombin are significantly populated (2:3 ratio) in vivo (53-56).
Na+ is required for the optimal cleavage of fibrinogen, PAR1, PAR3 and PAR4 as well as
activation of factors V, VIII and XI. More importantly, however, Na+ binding is
dispensable for activation of the anticoagulant protein C with or without thrombomodulin
(Figure 1.4). Therefore, Na+ binding is the major driving force behind the procoagulant,
prothrombotic and signaling functions of the blood (57). This explains why several
naturally occurring mutations of the prothrombin gene that affect residues linked to Na+
are associated with bleeding and why all anticoagulants thrombins engineered to date are
defective for Na+ binding (58).
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Further insights into how Na+ regulates the function of human thrombin came from the
work of Bush et. al. who observed that murine thrombin lacks Na+ activation, yet it
retains high catalytic activity towards all its physiological substrates (59). Structural and
kinetic analysis later revealed that the murine enzyme is adopts an E:Na+ conformation
both in the presence (personal communication) and absence of Na+ binding (60). The lack
of Na+ activation allows the murine enzyme to be more resistant to mutations that
destabilize the Na+ binding environment or the transmission of that binding to function.

After being overlooked in previous crystal structures, the Na+ binding site of thrombin
was finally identified unequivocally using Rb+ replacement in 1995 (61) and its definition
facilitated the subsequent identification of the analogous Na+ binding sites in Factor Xa
(62, 63), Factor IXa (50) Factor VIIa (64), activated protein C (65) and the thrombin
precursor meizothrombin-desF1 (51) (Figure 1.5). Structural analysis of E and E: Na+
reveals that a network of water molecules transmits the effect of Na+ from its binding site
to the active site. However, spectroscopic and mutagenesis evidence indicate that Na+
binding has long range allosteric effects that globally affect the enzyme (56, 66).

Because Na+ has a significant influence on the activity of all the vitamin K - dependent
clotting factors (42-44, 48-50, 52, 53) investigating the molecular determinants and
mechanism of its binding is key to understand the function and regulation of this family
of clotting enzymes. However, investigation of the effects of Na+ on these proteases has
mainly focused on thermodynamics of interaction and the resulting catalytic
enhancement, with little emphasis on characterizing the kinetic mechanism of Na+
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binding. In general, the kinetics of M+ binding to M+-activated enzymes remain for the
most part unexplored due to lack of convenient probes to monitor the interaction or the
difficulty of resolving rate constants for reactions that likely occur on a very fast time
scale.

My thesis project aims to fill this gap in the investigation of Type II Na+-activated
proteases by elucidating the kinetic mechanism of Na+ binding to vitamin K-dependent
clotting factors. Stopped flow and ultra-rapid continuous flow fluorescence techniques
were utilized to investigate the mechanism of Na+ binding by monitoring the associated
conformational changes in the µs and ms timescales. These studies, along with structural
analysis reveal the presence of inactive E* conformation that interconvert with the active
E form. To further understand the molecular determinants of E* and gain insight into its
role in substrate specificity, investigation of its properties were performed using a
combination of site-directed mutagenesis, enzyme catalysis, calorimetry and X-ray
crystallographic studies.

Several important questions are addressed in this thesis. What is the kinetic mechanism of
Na+ binding in all vitamin K-dependent clotting factors? What are the structural and
kinetic features of E* and what is the physiological role of the E* to E equilibrium?
Finally, can we alter substrate specificity by stabilizing E*? Due to the diversity of its
substrate and cofactor interactions, as well as its wealth of kinetic and structural data,
thrombin offers a unique opportunity to explore these questions.
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Chapter 2 gives a detailed description of the kinetics and thermodynamic properties of
the E* to E transition in human α-thrombin using stopped-flow measurements of intrinsic
fluorescence. The stopped-flow data presented in chapter 2 is complemented with the
ultra-rapid kinetic investigation from our collaborators in Stefano Gianni’s group to
establish the complete analysis of Na+ binding of thrombin.

Having established the presence of E* inactive conformation in wild type α-thrombin,
Chapter 3 explores the potential of stabilizing E* to abrogate catalytic function until a
suitable cofactor restores activity by triggering the E* to E transition. In α-thrombin, this
strategy can be utilized to turn off the procoagulant and prothrombotic functions of the
enzyme that do not require a cofactor, while maintaining the protein C anticoagulant
pathway in the presence of the cofactor TM. Stabilization of E* through mutation of the
autolysis loop provides a molecular mechanism to turn thrombin into an anticoagulant
with potential therapeutics for in vivo application.

Chapter 4 builds upon the results from the previous chapters and extend the mutagenesis
studies on the autolysis loop to explore the effects of its length and amino acid
composition in the E* to E transition and Na+ dependent allostery. Murine thrombin,
which is stabilized in an E: Na+ -like conformation, was utilized as a model to dissect the
role of the autolysis loop in the stabilization of E and E: Na+ conformations of human
thrombin.
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Chapter 5 describes the investigation of the kinetic mechanism of Na+ binding in clotting
factors VIIa, IXa, Xa and activated protein C. A binding mechanism similar to human αthrombin was observed in activated protein C, Factors IXa and Xa, indicating the
presence of E* is not unique to thrombin.

Finally, in chapter 6, we discuss how the knowledge gained from this thesis work can be
applied in future to enhance our understanding of protease function and to generate more
proficient enzymes for biological or industrial use.

Figure 1.4 Role of Na+ in the multiple roles of thrombin function. Na+ is the major driving force for the
procoagulant and prothrombotic functions of human thrombin. However, it is dispensable for the activation
of protein C. The E* is an inactive conformation incapable of interacting with Na+, substrates or inhibitors.
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Figure 1.5 The Na+ binding site of Vitamin K-dependent clotting factors. (A) In thrombin Na+ is
coordinated by four water molecules and two backbone carbonyl oxygens (221a, 224) while (B), the
reverse is true for FXa, two water molecules and four carbonyl oxygens (185a, 186, 222, 224). Note how
only a single loop is involved in thrombin but both 186- and 220-loops are coordinating the Na+ in FXa.
The Na+ sites in the other vitamin K-dependent clotting factors are similar to that of FXa. PDB codes
(1SG8, thrombin & 2BOK, FXa)
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Numerous enzymes with widely different functions, structures, and mechanisms require a monovalent cation (M!) for
optimal catalytic activity (1–3). In practically all cases reported
to date, M! activation is mediated by Na! or K! with high
selectivity (3, 4). Remarkable progress has been made during
the past decade in the structural characterization of such
enzymes. Structural studies have uncovered two basic mechanisms of activation, one in which M! functions as a cofactor by
bridging atoms of the protein and substrate in the active site
and another in which M! binds away from substrate and influences recognition and catalysis through an allosteric mecha-
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nism. A simple classification of M!-activated enzymes has been
proposed recently by merging information from kinetic and
structural studies (3). The classification groups enzymes based
on their M! specificity (Na! or K!) and the mechanism of
activation, cofactor-like (Type I) or allosteric (Type II).
Among Na!-activated Type II enzymes, thrombin has been
studied in considerable detail both functionally and structurally
(5–7). Na! binds near the primary specificity pocket, nestled
between the 186 and 220 loops (8, 9), and is required for efficient cleavage of the procoagulant factors fibrinogen (10), factors V (11), VIII (12), XI (13), and the prothrombotic factor
PAR1 (14), but not for activation of the anticoagulant protein C
(10, 15). Hence, Na! binding to thrombin controls key reactions responsible for the initiation, amplification, and feedback
inhibition of the coagulation cascade (16) as well as platelet
aggregation (7). Indeed, several naturally occurring mutations
of the prothrombin gene, like prothrombin Frankfurt (17),
Salakta (18), Greenville (19), Scranton (20), Copenhagen (21),
and Saint Denis (22), affect residues responsible for Na! binding (9) and are often associated with bleeding. Furthermore,
thrombin can be engineered for optimal anticoagulant activity
in vitro and in vivo by mutating residues linked to Na! binding
(15, 23–26).
Thrombin and a few other M!-activated enzymes like Trp
synthase (27, 28), pyruvate kinase (29, 30), Hsc70 (31), !-galactosidase (32, 33), and inosine monophosphate dehydrogenase
(34) have been the subject of detailed treatments of the kinetics
of M! activation. At steady state, Na! promotes diffusion into
the active site and acylation of substrate by thrombin (35–37).
The binding affinity is relatively weak, with a Kd in the millimolar range (35) as found for many other M!-activated enzymes
(1– 4), and changes significantly with temperature (38 – 40).
However, the kinetics of M! binding to M!-activated enzymes
in general remain for the most part unexplored due to the difficulty of resolving rate constants for reactions that likely occur
on a very fast time scale (4). In the case of thrombin, earlier
studies have suggested that Na! binds in a two-step mechanism
with a fast phase occurring within the dead time of the spectrometer (2 ms), followed by a slow phase in the 30-ms time
scale at 5 °C (41). In the present study, we revisit these earlier
observations and address the kinetic mechanism of Na! binding to thrombin in more detail. We identify the Trp residues
responsible for the spectral changes and the precise mechanism
that gives rise to the two-step components of Na! binding.

MATERIALS AND METHODS
Site-directed mutagenesis of human thrombin was carried
out in a HPC4-modified pNUT expression vector (15, 42), using
the QuikChange site-directed mutagenesis kit from Stratagene

23

JOURNAL OF BIOLOGICAL CHEMISTRY

40049

Downloaded from www.jbc.org at Washington University, on December 9, 2009

The kinetic mechanism of Na! binding to thrombin was
resolved by stopped-flow measurements of intrinsic fluorescence. Na! binds to thrombin in a two-step mechanism with a
rapid phase occurring within the dead time of the spectrometer
(<0.5 ms) followed by a single-exponential slow phase whose
kobs decreases hyperbolically with increasing [Na!]. The rapid
phase is due to Na! binding to the enzyme E to generate the
E:Na! form. The slow phase is due to the interconversion
between E* and E, where E* is a form that cannot bind Na!.
Temperature studies in the range from 5 to 35 °C show significant enthalpy, entropy, and heat capacity changes associated
with both Na! binding and the E to E* transition. As a result,
under conditions of physiologic temperature and salt concentrations, the E* form is negligibly populated (<1%) and thrombin is almost equally partitioned between the E (40%) and E:Na!
(60%) forms. Single-site Phe mutations of all nine Trp residues
of thrombin enabled assignment of the fluorescence changes
induced by Na! binding mainly to Trp-141 and Trp-215, and to
a lesser extent to Trp-148, Trp-207, and Trp-237. However, the
fast phase of fluorescence increase is influenced to different
extents by all Trp residues. The distribution of these residues
over the entire thrombin surface demonstrates that Na! binding induces long-range effects on the structure of the enzyme as
a whole, contrary to the conclusions drawn from recent structural studies. These findings elucidate the mechanism of Na!
binding to thrombin and are relevant to other clotting factors
and enzymes allosterically activated by monovalent cations.

Supplemental Material can be found at:
http://www.jbc.org/content/suppl/2006/10/31/M608600200.DC1.html

Na! Binding to Thrombin

F#

F 0 $ F1 Kapp%Na!&
1 $ Kapp%Na!&

(Eq. 1)

where F0 and F1 are the values of F in the absence and under
saturating [Na!] and Kapp is the apparent equilibrium association constant for Na! binding (see below). The value of F0 corresponds to the base-line reading.
The simplest kinetic scheme accounting for the two-step
mechanism of Na! binding detected by stopped-flow measurements is given by Scheme 1.
k #1 KA
E* 9
|
= E N E:Na!
k1

The free enzyme exists in equilibrium between two forms, E*
and E, that interconvert with kinetic rate constants k1 and k#1.
Of these forms, only E can interact with Na! with an equilibrium association constant KA to generate the E:Na! form. The
fast phase detected by rapid kinetics is due to the binding of
Na! to E to generate E:Na!. Analysis of the fast phase was
carried out according to Equation 2, which is analogous to
Equation 1,
F#

The abbreviations used are: PEG, polyethylene glycol; MES, 4-morpholineethanesulfonic acid.
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(Eq. 2)

where Fi is the value of F under saturating [Na!] (Fi $ F1) and
KA is the intrinsic equilibrium association constant for Na!
binding. The slow phase is due to the interconversion between
E* and E with an observed rate constant as shown in Equation 3.
k obs # k1 $ k#1

1
1 $ KA%Na!&

(Eq. 3)

The value of kobs is expected to decrease with increasing [Na!]
from k1 ! k#1 ([Na!] ' 0) to k1 ([Na!] ' ∞). Analysis of kobs
yields k1, k#1, and a value of KA that is independent from that
derived from analysis of the amplitude of the fast phase according to Equation 2. In the event of a mutation that abrogates the
fast phase, the effect of Na! binding can still be detected from
measurements of kobs (see “Results”). The alternative two-step
mechanism as shown in Scheme 2
k#1
KA
|
= E*:Na!
E N E:Na! 9
k1
SCHEME 2

where a slow isomerization follows the rapid binding of Na!
leads to an observed rate constant as shown in Equation 4.
KA%Na!&
k obs # k#1 $ k1
1 $ KA%Na!&

(Eq. 4)

In this case, the value of kobs is expected to increase with
increasing [Na!] from k#1 ([Na!] ' 0) to k1 ! k#1 ([Na!] ' ∞).
Hence, the dependence of kobs on [Na!] is of diagnostic value
and rules out Scheme 2 in favor of Scheme 1 (see “Results”).
There is a relationship between the apparent equilibrium
association constant Kapp derived from Equation 1 and the
intrinsic equilibrium association constant KA derived from
Equation 2 or 3. The value of Kapp can also be derived from
equilibrium titrations of intrinsic fluorescence (35, 39 – 41, 46,
47) or linkage studies (38, 46, 48). The value of KA, on the other
hand, can only be derived from rapid kinetic studies. Because of
the presence of E, E*, and E:Na! in Scheme 1, at equilibrium
one has (49) Equation 5.
K app #

SCHEME 1
2

F 0 $ Fi KA%Na!&
1 $ KA%Na!&

KA
KA
#
k#1 1 $ r
1$
k1

(Eq. 5)

The parameter r ' [E*]/[E] measures the population of E* relative to E. Under conditions where r $$ 1 and the free form is
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(La Jolla, CA) as described (9, 39). Expression of thrombin
mutants was carried out in baby hamster kidney cells. Mutants
were activated with the prothrombinase complex between 40
and 60 min at 37 °C. Enzymes used in the activation were from
Enzyme Research (South Bend, IN). Mutants were purified to
homogeneity by fast protein liquid chromatography using
Resource Q and S columns with a linear gradient from 0.05 to
0.5 M choline chloride (ChCl), 5 mM MES, pH 6, at room temperature. Active site concentrations were determined by titration with hirudin (43). All nine Trp residues of thrombin were
mutated to Phe by single-site substitutions. The conservative
replacement did not change the kinetic properties of the constructs, which retained activity toward substrates and Na! activation comparable with wild-type (data not shown). Murine
thrombin was prepared as reported elsewhere (44).
Stopped-flow fluorescence measurements of Na! binding to
thrombin were carried out with an Applied Photophysics SX20
spectrometer, using an excitation of 280 nm and a cutoff filter at
305 nm. Samples of thrombin at a final concentration of 50 nM
were mixed 1:1 with 60-"l solutions of the same buffer (5 mM
Tris, 0.1% polyethylene glycol (PEG),2 pH 8.0, at 15 °C) containing variable amounts of NaCl (up to 400 mM) kept at constant
ionic strength of 400 mM with ChCl. The baseline was measured with 400 mM ChCl in the mixing syringe. Each trace was
determined in quadruplicate. Na! binding studies were carried
out for wild-type thrombin in the temperature range 5–35 °C.
The pH was precisely adjusted at room temperature to obtain
the value of 8.0 at the desired temperature. Tris buffer has a pKa
of 8.06 at 25 °C and a temperature coefficient of "pKa/"T of
#0.027 (45). These properties ensured buffering over the entire
temperature range examined.
The fluorescence increase observed upon Na! binding has
an initial rapid phase that cannot be resolved within the dead
time ($0.5 ms) of the spectrometer, followed by a single exponential slow phase with a kobs that decreases as [Na!] increases
(see “Results”). The total change in fluorescence calculated
from the sum of the amplitudes of the fast and slow phases
coincides with the value of F determined by equilibrium measurements of intrinsic fluorescence. The value of F as a function
of [Na!] was fit according to Equation 1 (39)
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mates the true Na! binding affinity KA. Hence, it is very important to know how r changes under conditions of interest to
correctly interpret Na! binding in terms of the process that
converts E to E:Na!.
The temperature dependence of Kapp, KA, and r yields the
thermodynamic parameters associated with the underlying
processes according to Equation 6 (39)
#ln K #

!

"H0 1 "S0 "CP
T0
T
1 % % ln
%
$
R T
R
R
T
T0

"

(Eq. 6)

where K is Kapp, KA, or r, "H0 and "S0 are the enthalpy and
entropy changes at the reference temperature T0 ' 298.15 K,
"CP is the heat capacity change, R the gas constant, T the absolute temperature. The van’t Hoff plot of #lnK versus 1/T is
linear when "CP ' 0 and curves upward when "CP $ 0.
FIGURE 2. Values of kobs for the slow phase of fluorescence increase due
to Na! binding to thrombin (see Fig. 1) as a function of [Na!] in the temperature range 5–35 °C. Shown are the results pertaining to 5 (black circles),
10 (gray circles), 15 (red circles), 20 (green circles), 25 (blue circles), 30 (yellow
circles), and 35 (magenta circles) °C. Experimental conditions were 50 nM
thrombin, 5 mM Tris, 0.1% PEG, pH 8.0. The [Na!] was changed by keeping the
ionic strength constant at 400 mM with ChCl. Continuous lines were drawn
according to Equation 3 under “Materials and Methods” with best-fit parameter values listed in Table 1.

essentially all E, the value of Kapp coincides with KA. However,
under conditions where r is significant, a sizable fraction of free
thrombin exists in the E* form and the value of Kapp underestiDECEMBER 29, 2006 • VOLUME 281 • NUMBER 52
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RESULTS
Na! binding to human thrombin gives rise to a significant
increase in intrinsic fluorescence (35, 39 – 41, 46, 47). The
change occurs in two steps, clearly revealed by stopped-flow
measurements (Fig. 1A). A fast phase, whose amplitude
increases with [Na!], occurs within the dead time of the spectrometer ($0.5 ms) and is followed by a single-exponential slow
phase whose kobs decreases with increasing [Na!]. Control
experiments run with murine thrombin, an enzyme devoid of
Na! activation (44), show no change in fluorescence even at
200 mM Na! (Fig. 1B). The dependence of kobs on [Na!] is
hyperbolic (Fig. 2) and is consistent with the mechanism
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FIGURE 1. A, kinetic traces of Na! binding to human thrombin in the 0 –250-ms time scale. Shown are the traces obtained at 0 (black circles), 5 (red circles), 10
(green circles), and 50 (blue circles) mM Na!. Notice how the binding of Na! obeys a two-step mechanism, with a fast phase completed within the dead time
($0.5 ms) of the spectrometer, followed by a single-exponential slow phase. The kobs for the slow phase decreases with increasing [Na!] (see also Fig. 2), as is
evident from the plot. Experimental conditions were 50 nM thrombin, 5 mM Tris, 0.1% PEG, pH 8.0, at 15 °C. The [Na!] was changed by keeping the ionic strength
constant at 400 mM with ChCl. Continuous lines were drawn using the expression a{1 # exp(#kobst)} ! b with best-fit parameter values: black circles, a ' 0 (
0 V, kobs ' 0 ( 0 s#1, b ' 8.19 ( 0.01 V; red circles, a ' 0.11 ( 0.02 V, kobs ' 170 ( 10 s#1, b ' 8.39 ( 0.02 V; green circles, a ' 0.15 ( 0.02 V, kobs ' 150 ( 10
s#1, b ' 8.46 ( 0.02 V; blue circles, a ' 0.37 ( 0.01 V, kobs ' 130 ( 10 s#1, b ' 8.54 ( 0.01 V. B, kinetic traces of Na! binding to thrombin wild type and mutants
in the 0 –250-ms time scale expressed relative to the base-line value F0 to enable comparison. Shown are the traces obtained at 200 mM Na! for human
thrombin (black circles), mutants W141F (red circles), and W215F (green circles). Also shown, as a control, is the trace obtained at 200 mM Na! for murine
thrombin (blue circles), which is devoid of Na! activation. Notice how mutation of Trp-141 and Trp-215 essentially abolishes the fast phase seen in the wild type
(see panel A) and reduces significantly the total fluorescence change associated with Na! binding (see also Fig. 3 and Table 2). Experimental conditions were
50 nM thrombin, 5 mM Tris, 0.1% PEG, pH 8.0, at 15 °C. Continuous lines were drawn using the expression a{1 # exp(#kobst)} with best-fit parameter values: black
circles, a ' 0.36 ( 0.02 V, kobs ' 111 ( 7 s#1, b ' 0.37 ( 0.02 V; red circles, a ' 0.21 ( 0.02 V, kobs ' 84 ( 8 s#1, b ' 0.02 ( 0.02 V; green circles, a ' 0.20 ( 0.01
V, kobs ' 130 ( 10 s#1, b ' #0.01 ( 0.01 V; blue circles, a ' 0 ( 0 V, kobs ' 0 ( 0 s#1, b ' 0.00 ( 0.01 V.
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TABLE 1
Fluorescence and Na! binding parameters for wild-type thrombin as a function of temperature
The parameters F0, Fi, and F1 defining "Fi ' Fi # F0 and "Ft ' F1 # F0 were derived from analysis of the data in Fig. 3, A and B, using Equations 1 and 2 under “Materials
and Methods.” The values of Kapp were derived from analysis of the data in Fig. 3A according to Equation 1. The values of KA were derived from analysis of the data in
Fig. 3B according to Equation 2, and Fig. 2 according to Equation 3, together with the values of k1 and k#1. r is the ratio k#1/k1. Note how the values of Kapp and KA obtained
independently obey Equation 5 under “Materials and Methods.”
T

F0

Fi

F1

"Fi/F0

"Ft/F0

°C

V

V

V

%

%

5
10
15
20
25
30
35

8.36 ( 0.02
8.32 ( 0.03
8.19 ( 0.01
7.94 ( 0.03
8.18 ( 0.03
8.21 ( 0.02
8.16 ( 0.02

8.74 ( 0.02
8.74 ( 0.03
8.59 ( 0.02
8.18 ( 0.03
8.57 ( 0.03
8.49 ( 0.02
8.40 ( 0.02

9.09 ( 0.02
9.01 ( 0.03
9.03 ( 0.01
8.51 ( 0.03
8.94 ( 0.03
8.96 ( 0.02
8.93 ( 0.02

4.5
5.0
4.9
3.0
4.8
3.4
2.9

8.7
8.3
10.3
7.1
9.3
9.1
9.4

depicted in Scheme 1 and Equation 3. That supports the conclusion that, in the absence of Na!, thrombin exists in equilibrium between two conformations, E* and E, and that only E can
be converted to the E:Na! form. The binding of Na! to E gives
rise to the fast phase. The slow phase detected by stopped-flow
measurements is the result of the interconversion between E*
and E that takes place on a time scale of milliseconds.
The sum of the amplitudes of the slow and fast phases
changes hyperbolically with [Na!] (Fig. 3A) and recapitulates
the behavior observed by intrinsic fluorescence measurements
at equilibrium (35, 39 – 41, 46, 47). Analysis of such curves in
the temperature range 5–35 °C enables determination of Kapp
from Equation 1 (Table 1). A van’t Hoff plot of the Kapp values is
shown in Fig. 4 and reveals a curvature conducive to the presence of a heat capacity change of #500 cal/mol/K, consistent
with previous results (38 – 40). Analysis of the amplitude of the
fast phase as a function of [Na!] (Fig. 3B) according to Equation
2 enables the determination of KA (Table 1). These values of KA
are practically identical to those derived independently from
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Kapp
M

#1

220 ( 20
180 ( 20
100 ( 10
68 ( 7
46 ( 5
24 ( 2
13 ( 1

KA

k1

k#1

#1

s#1

s#1

M

370 ( 40
300 ( 40
160 ( 20
90 ( 9
57 ( 4
28 ( 2
15 ( 1

52 ( 2
78 ( 4
115 ( 3
166 ( 4
224 ( 4
312 ( 4
431 ( 10

48 ( 2
75 ( 4
83 ( 6
65 ( 8
34 ( 4
27 ( 8
23 ( 4

r
0.92
0.96
0.72
0.39
0.15
0.086
0.053

analysis of kobs as a function of [Na!] according to Equation 3
(Fig. 2), which also enables resolution of k1 and k#1 (Table 1).
The van’t Hoff plot of the KA values is curved, as for Kapp, due to
a heat capacity change of #500 cal/mol/K (Fig. 4). This proves
that the heat capacity change reported previously for the values
of Kapp (38 – 40) reflects an intrinsic property of Na! binding to
thrombin and is not the result of the pre-existing equilibrium
between E and E*. In fact, from the definition of Kapp in Equation 5, it can be seen that the E-E* equilibrium gives rise to an
apparent heat capacity change when the value of r changes with
temperature, even if no heat capacity change is associated with
KA and/or r. The direct determination of KA from rapid kinetic
data resolves the transition from E to E:Na! in Scheme 1 and
decouples this process from the linked equilibrium between E
and E*. The temperature dependence of KA then offers direct
validation of the heat capacity change associated with Na!
binding as a basic thermodynamic property of thrombin
(38 – 40).
Binding of Na! is characterized by a large enthalpy change of
VOLUME 281 • NUMBER 52 • DECEMBER 29, 2006
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FIGURE 3. A, Na! binding curves of thrombin obtained from the total change in intrinsic fluorescence measured as the sum of the amplitudes of the fast and
slow phases determined by stopped-flow kinetics (see Fig. 1). Shown are the results pertaining to 5 (black circles), 10 (gray circles), 15 (red circles), 20 (green
circles), 25 (blue circles), 30 (yellow circles), and 35 (magenta circles) °C. Experimental conditions were 50 nM thrombin, 5 mM Tris, 0.1% PEG, pH 8.0. The [Na!] was
changed by keeping the ionic strength constant at 400 mM with ChCl. Continuous lines were drawn according to Equation 1 under “Materials and Methods”,
with best-fit parameter values listed in Table 1. B, Na! binding curves of thrombin obtained from the amplitude of the fast phase of fluorescence increase
determined by stopped-flow kinetics (see Fig. 1). Shown are the results pertaining to 5 (black circles), 10 (gray circles), 15 (red circles), 20 (green circles), 25 (blue
circles), 30 (yellow circles), and 35 (magenta circles) °C. Experimental conditions were 50 nM thrombin, 5 mM Tris, 0.1% PEG, pH 8.0. The [Na!] was changed by
keeping the ionic strength constant at 400 mM with ChCl. Continuous lines were drawn according to Equation 2 under “Materials and Methods” with best-fit
parameter values listed in Table 1.
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#22 kcal/mol that is compensated by a large entropy loss of
#64 cal/mol/K (Fig. 4). The enthalpy change is due to formation of the six ligating interactions in the coordination shell that
also involve four buried water molecules (3, 4, 9). The entropy
change reflects the uptake and ordering of water molecules
within the channel embedding the primary specificity pocket
and the active site linked to the occupancy of the Na! site (9).
As a result of the enthalpy-entropy energetic compensation, the
binding affinity of Na! is relatively weak (Kd in the mM range),
as seen for many other M!-activated enzymes (3, 4). An important consequence of the large enthalpy change is that the value
of KA becomes only about 10 M#1 at 37 °C, which implies that
under physiologic conditions of temperature and [NaCl] ' 140
mM thrombin is only 60% bound to Na!, as first documented in
1992 (35). This makes thrombin optimally poised for allosteric
regulation in vivo, where the Na!-bound and Na!-free forms
are targeted toward procoagulant and anticoagulant roles,
respectively (7, 10).
It is of particular importance to structurally assign the spectral changes linked to Na! binding to thrombin. Trp-215 in the
aryl binding site has been identified as a major fluorophore
responsible for the spectral change (48), but a rigorous test of
the contribution of all nine Trp residues of thrombin has not
been carried out. Previous studies investigated the role of Trp60d, Trp-96, Trp-148, Trp-207, and Trp-215 with Phe substitutions, but the analysis involved the activity toward thrombin
substrates and not Na! binding (50). Fig. 5 shows the fluorescence enhancement due to Na! binding for the Phe mutants of
all nine Trp residues of thrombin. The Phe mutations of the
DECEMBER 29, 2006 • VOLUME 281 • NUMBER 52

nine Trp residues of thrombin cause few, if any, changes in the
kinetic and equilibrium properties of the enzyme toward Na!
(Table 2). The Trp 3 Phe substitution therefore provides an
optimal adiabatic perturbation of the indole moiety and probes
selectively the changes monitored by fluorescence spectroscopy. The data in Fig. 5 refer to the total fluorescence change,
F1 # F0 in Equation 1 (black bars) or the amplitude of the fast
phase, Fi # F0 in Equation 2 (gray bars), both relative to the
base-line value F0. The 10% total increase in fluorescence
observed for wild type is retained by five Trp mutants, namely,
W29F, W51F, W60dF, W96F, and W237F. Two mutants,
W148F and W207F, experience )30% loss in total fluorescence
change. On the other hand, W141F and W215F lose )70% of
the total fluorescence change. Inspection of the fast component
of the fluorescence change is even more informative. This
phase monitors directly Na! binding to E to generate the E:Na!
form. In the wild type, the amplitude of the fast phase, Fi # F0
(see Table 1 and Figs. 1B and 3B), is about half the amplitude of
the total fluorescence change, F1 # F0 (see Table 1 and Figs. 1A
and 3A). The amplitude of the fast phase is perturbed in all Trp
mutants, even when the total fluorescence change is the same as
for wild type (Figs. 1 and 5). Because Trp residues are distributed over the entire structure of thrombin, and their distance
from the bound Na! ranges from 13 (Trp-215) to 35 (Trp-51)
Å, binding of Na! to E likely elicits effects well beyond the
immediate environment of the Na! site and perturbs the structure of thrombin as a whole. This is in agreement with recent
functional mapping of the Na!-induced allosteric transition of
thrombin (51). The amplitude of the fast phase increases significantly relative to wild type for the W29F, W51F, W60dF, and
W96F mutants. On the other hand, the amplitude decreases
significantly for W148F, W207F, and W237F and completely
disappears for W141F and W215F. Hence, Trp-215 but also
Trp-141 are major reporters of the process of Na! binding to
thrombin. Trp-148, Trp-207, and Trp-237 also contribute to
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FIGURE 4. van’t Hoff plots of Na! binding to thrombin. Shown are the
values of Kapp (open circles) and KA (black circles) obtained from stopped-flow
kinetics in the temperature range 5–35 °C (see Table 1). The plot is curved in
both cases, signaling the presence of a heat capacity change. Also shown is
the temperature dependence of #log r (gray circles, dimensionless units),
measuring the equilibrium between E and E* in Scheme 1 (see Table 1). This
parameter too is associated with significant curvature in the plot, signaling a
large heat capacity change. Experimental conditions were 5 mM Tris, 0.1%
PEG, pH 8.0. Continuous lines were drawn according to Equation 6 under
“Materials and Methods” with best-fit parameter values: open circles, "H0 '
#18.9 ( 0.9 kcal/mol, "S0 ' #56 ( 3 cal/mol/K, "CP ' #500 ( 100 cal/
mol/K; black circles, "H0 ' #21.5 ( 0.9 kcal/mol, "S0 ' #64 ( 3 cal/mol/K,
"CP ' #500 ( 100 cal/mol/K; gray circles, "H0 ' #23 ( 2 kcal/mol, "S0 '
#81 ( 8 cal/mol/K, "CP ' #900 ( 300 cal/mol/K.

FIGURE 5. Fluorescence change induced by Na! binding to wild type
and the Phe mutants of all nine Trp residues of human thrombin.
Shown are the values listed in Table 2 for the total change in intrinsic
fluorescence measured as F1 # F0 (black bars) or the amplitude of the fast
phase measured as Fi # F0 (gray bars). All values are expressed as % change
relative to F0. Experimental conditions were 50 nM thrombin, 5 mM Tris,
0.1% PEG, pH 8.0, at 15 °C. The [Na!] was changed by keeping the ionic
strength constant at 400 mM with ChCl.
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TABLE 2
Fluorescence and Na! binding parameters for wild-type thrombin and mutants

a

wt
W29F
W51F
W60dF
W96F
W141F
W148F
W207F
W215F
W237F

F0

Fi

F1

"Fi/F0

"Ft/F0

V

V

V

%

%

8.19 ( 0.01
8.17 ( 0.02
8.15 ( 0.01
8.13 ( 0.01
8.13 ( 0.03
8.02 ( 0.01
8.18 ( 0.02
8.15 ( 0.01
8.12 ( 0.01
8.14 ( 0.02

8.59 ( 0.02
8.69 ( 0.02
8.70 ( 0.02
8.73 ( 0.03
8.70 ( 0.03
8.02 ( 0.01
8.35 ( 0.02
8.28 ( 0.02
8.12 ( 0.01
8.36 ( 0.01

9.03 ( 0.01
9.02 ( 0.02
9.04 ( 0.01
9.05 ( 0.01
8.98 ( 0.03
8.24 ( 0.01
8.69 ( 0.02
8.73 ( 0.01
8.34 ( 0.01
9.08 ( 0.01

4.9
6.4
6.7
7.4
7.0
0.0
2.1
1.6
0.0
2.7

10.3
10.4
10.9
11.3
10.4
2.7
6.2
7.1
2.7
11.5

Kapp
M

#1

100 ( 10
58 ( 6
100 ( 10
89 ( 6
70 ( 10
110 ( 10
81 ( 8
120 ( 10
59 ( 8
110 ( 10

KA

k1

k#1

#1

s#1

s#1

M

160 ( 20
85 ( 7
170 ( 30
140 ( 10
110 ( 10
170 ( 10
130 ( 10
190 ( 10
110 ( 10
170 ( 10

115 ( 3
126 ( 4
114 ( 3
132 ( 2
133 ( 2
79 ( 1
95 ( 2
89 ( 2
118 ( 3
101 ( 2

83 ( 6
74 ( 4
87 ( 6
77 ( 9
69 ( 2
40 ( 9
72 ( 4
78 ( 2
81 ( 7
68 ( 3

r
0.72
0.59
0.76
0.58
0.52
0.51
0.76
0.88
0.69
0.67

Da
Å

24
35
21
27
23
21
23
13
30

Distance from the C&2 atom of the Trp residue to the bound Na! in the crystal structure of the Na!-bound form 1SG8 (9). All parameters were derived as shown in Table I.
Note how the values of Kapp and KA obtained independently obey Equation 5 under “Materials and Methods.”
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previous study (41), we did observe
significant photobleaching that
affected base-line stability, reproducibility, and extent of fluorescence change (see supplemental
data). When we further reduced the
thrombin concentration down to 5
nM, the results lacked the optimal
reproducibility observed at 50 nM.
Significant photobleaching was
acknowledged in the previous study
(41), but not resolved. The previous
study was carried out at 5 °C, where
condensation in the cell is very significant and must be eliminated
!
FIGURE 6. Ribbon plot of thrombin in the Na -bound form, portraying the structure 1SG8 (9) with the
active site in the front (A) or rotated 180° along the y-axis (B). Shown are the side chains of the catalytic with constant N2 flushing. We
residues His-57, Asp-102, and Ser-195 and the side chain of Asp-189. Na! is rendered as a green ball. The nine found that the temperature range of
Trp residues of the enzyme are shown with their side chains in orange. The contribution of these residues to the 15–25 °C is optimal to resolve the
fluorescence change induced by Na! binding is shown in Fig. 5 and Table 2. The A chain was removed for
range of kobs linked to Na! binding.
clarity.
Last, but not least, the pKa of Tris
the spectral change, whereas Trp-29, Trp-51, Trp60d, and buffer at 5 °C is 8.60 (45), which makes it problematic to buffer
Trp-96 produce changes that oppose those of the other fluoro- a solution at pH 7.4 as used in the previous study (41).
phores because their replacement to Phe actually enhances the
Our results add mechanistic significance to previous studies
fluorescence change due to Na! binding.
of Na! binding because of the use of Phe mutations of all nine
Trp residues of thrombin. The fast phase of fluorescence
DISCUSSION
increase directly linked to the transition from E to E:Na! in
The results presented here expand and clarify the scenario Scheme 1 is affected in all Phe mutants, vouching for a global
offered by the only previous investigation of Na! binding to effect of Na! binding on thrombin structure. The contributions
thrombin using rapid kinetics (41). The earlier study was carof single Trp residues are not additive, lending support to the
ried out at 5 °C and ionic strength values of 0.3 and 2.0 M, using
hypothesis that some of the environments in which they reside
500 nM thrombin. Two phases were identified, as shown in Fig.
may be coupled allosterically. The coupling may ensure propa!
1A, but no dependence of kobs on [Na ] could be detected
gation of long-range effects originating at the Na! site via a
!
below 500 mM [Na ]. This made interpretation of the results
particularly cumbersome and did not support the use of simple limited number of structural conduits. Trp-141 and Trp-215
a large contribution to the fluorescence change induced
mechanisms like Scheme 1 or Scheme 2. The study, however, make !
by
Na
binding, and their mutation to Phe abrogates the fast
uncovered the pre-existing equilibrium between E and E* as
phase
completely.
This implies that the environments of Trpdepicted in Scheme 1. There are several reasons why our
!
141
and
Trp-215
change
in the E* to E conversion, and more
results, and especially the dependence of kobs on [Na ], differ in
drastically
in
the
conversion
of E to E:Na!. The important role
part from those reported previously. The SX20 spectrometer is
a much improved version of the SX17 model used previously of Trp-215 has been reported before (48). This is the closest Trp
!
(41) and features a shorter dead time and higher signal resolu- residue to the bound Na (13 Å) and defines most of the aryl
tion and stability. The thrombin concentration used in our binding site involved in substrate recognition (5, 9, 52). The
measurements (50 nM) did not result in any photobleaching, importance of Trp-141 is unanticipated. However, recent
thereby eliminating the need to correct for the effect when fit- structures of thrombin document a flip in the indole ring of
ting experimental data. When using 500 nM thrombin, as in the Trp-141 in the absence of Na! similar to that observed for
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unraveled under the constrained environment of a crystal lattice or available structures of the slow and/or fast forms are not
representative of the full landscape of conformational transitions induced by Na! binding. Indeed, functional mapping of
the slow 3 fast transition suggests a more global involvement
of thrombin residues (51).
Structural assignments for the E* form are equally problematic. In a previous study on the kinetics of Na! binding to
thrombin, E* was interpreted as an “inactive” slow form unable
to bind Na! and substrate or inhibitors at the active site (41).
The conclusion was drawn from data showing that the binding
of inhibitors to thrombin was also linked to increases in intrinsic fluorescence and obeyed a mechanism similar to that of Na!
binding (41). The hypothesis of E* being an inactive conformation of the slow form, as originally suggested by Lai et al. (41),
has gained prominence recently in the context of several structures of inactive forms of thrombin in the Na!-free form that
have appeared in the literature. These structures differ drastically from the active slow form E (9, 57) and share disorder or
collapse of the Na! site and steric blockage of the active site (49,
58 – 61). We have recently shown (62) that these inactive structures are likely the result of mutations introduced in the
enzyme (58, 59) and/or artifacts of crystal packing (49, 60, 61). A
recent structure of thrombin obtained in the absence of inhibitors and salts appears to be a genuine inactive slow form,
devoid of artifactual effects due to mutations in the Na! site or
crystal packing (62). The structure has the Na! site obliterated
by the side chain of Arg-187 and the active site occluded by the
repositioning of the side chains of Trp-215 and Arg-221a. The
drastic movement of Trp-215 would do justice to the dominant
role played by this residue in the fluorescence changes reported
in our study. However, even this structure lacks significant
changes around all other Trp residues. Hence, evidence that
thrombin can assume an inactive slow form under crystallographic conditions is strong (62), but the connection with
the functional properties of the enzyme in solution remains
weak. The kinetic signatures of Na! activation do not
require inactive conformations of thrombin and indeed
refute (4, 49) simplistic “alternative” models based on the
equilibrium of active and inactive forms (61).
The data presented in this study vouch for E* being a form
of thrombin unable to bind Na! and not necessarily inactive
toward substrates or inhibitors. In fact, a conformation of
thrombin with the pore of entry to the Na! binding site (4, 39)
occluded would fit the description of E* and would still retain
activity toward substrates and inhibitors. Whether inactive
conformations of thrombin in the slow form exist in solution
remains to be demonstrated by future studies of rapid kinetics
involving the library of Trp mutants presented here in order to
structurally assign the observed spectral changes and confirm
that they have the same origin as those linked to Na! binding.
However, even if future studies in solution prove that E* is
indeed an inactive slow form, then its possible physiologic role
should be clarified. Based on the data in Fig. 5, E* represents
$1% of the population of thrombin molecules at 37 °C, which
raises questions about its possible functional role in vivo. This
conundrum does not apply to the active slow form, which contributes 40% of the thrombin molecules in vivo and whose anti-
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Trp-215 (49). Trp-141 is buried in a strategic location between
the autolysis loop and exosite I, and its linkage with the bound
Na!, situated 23 Å away, vouches for a pivotal role in communicating changes from the Na! site to exosite I (Fig. 6). Among
the other residues that contribute to the fluorescence change
and the fast phase, Trp-148 is located in the middle of the highly
flexible autolysis loop, 21 Å away from the bound Na!, and is
62% exposed to solvent (52), whereas Trp-207 is completely
buried in the back of the catalytic chain, 23 Å away from the
bound Na!, and in hydrophobic contact with Trp-29 and residues of the A chain (Fig. 6). Because of their proximity, Trp-207
and Trp-29 may function as a single fluorophore and/or quench
each other. It is interesting that the Phe mutation of Trp-29
enhances the amplitude of the fast phase, as though changes
affecting Trp-207 are better reported in the absence of Trp-29.
A similar scenario can be envisioned for Trp-51 and Trp-237
(Fig. 6), whose hydrophobic coupling may result in overlapping
spectral effects with Trp-51 actually hindering the full response
of Trp-237 to Na! binding. Finally, the effects seen with the
highly solvent-exposed Trp-60d and Trp-96 (Fig. 6) suggest
that these residues may be quite flexible and capable of probing
different environments that reduce the fluorescence response
to Na! binding.
It is of interest to correlate the new information arising from
stopped-flow measurements of the mechanism of Na! binding
to thrombin with existing structural data. The three species in
Scheme 1 portray thrombin in the Na!-free (E and E*) and
Na!-bound (E:Na!) forms, and the data presented here demonstrate that Na! binds to thrombin in a two-step mechanism
consistent with Scheme 1. The activation effect of Na! on
thrombin has very clear kinetic signatures and specifically
involves an increase in kcat and a decrease in Km (35–37, 49, 53,
54). Such a “modifier” effect on kcat has long been known to be
of diagnostic value (55) and unequivocally proves the existence
of two active forms in equilibrium, one Na! free with low kcat
and one Na! bound with high kcat (4, 49). E and E:Na! in
Scheme 1 are the two active forms of thrombin that account for
the dependence of kcat on [Na!] and correspond to the slow (E)
and fast (E:Na!) forms originally defined by Wells and Di Cera
(35). The structures of these two forms have been solved
recently (9). Basic differences between them involve the orientation of Asp-189 in the primary specificity pocket, Ser-195 in
the active site, and the reorganization of a water network that
connects the Na! site to the active site Ser-195 located 16 Å
away. The orientation of Asp-189 in the fast form optimizes
docking of the guanidinium group of Arg at the P1 position of
substrate. The O' atom of Ser-195 in the fast form is within
H-bonding distance of the catalytic His-57. The H-bond is
required for efficient catalysis (56) and is broken in the slow
form. The network of water molecules ensures the long-range
communication between the bound Na! and the active site that
is at the basis of thrombin allostery. The increase in the number
and ordering of water molecules linked to Na! binding also
explains the large entropy loss and negative heat capacity
change associated with this process. Unfortunately, the differences between the slow and fast forms reported recently (9) do
not involve Trp residues that contribute to the spectral changes
linked to Na! binding. Either such changes are too subtle to be

Supplemental Material can be found at:
http://www.jbc.org/content/suppl/2006/10/31/M608600200.DC1.html

Na! Binding to Thrombin
coagulant role is well established (7, 10, 15). Nonetheless, E*
carries considerable mechanistic significance for Na! binding
to thrombin and may become populated under the effect of
mutations or conditions that involve allosteric effectors to be
identified. In addition, E* is an intriguing new variable to be
taken into consideration when studying Na! binding to other
clotting factors and M!-activated enzymes.
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Serine proteases of the trypsin family are responsible for
digestion, blood coagulation, fibrinolysis, development, fertilization, apoptosis, and immunity (1). Activation of the protease
requires the transition from a zymogen form (2) and formation
of an ion pair between the newly formed amino terminus of the
catalytic chain and the side chain of the highly conserved residue Asp194 (chymotrypsinogen numbering) next to the catalytic Ser195. This ensures substrate access to the active site and
proper formation of the oxyanion hole contributed by the backbone N atoms of Ser195 and Gly193 (3). The zymogen 3 protease conversion is classically associated with the onset of catalytic activity (3, 4) and provides a useful paradigm for
understanding key features of protease function and regulation.
Recent kinetic (5) and structural (6, 7) studies of thrombin,
the key protease in the blood coagulation cascade (8), have
drawn attention to a significant plasticity of the trypsin fold that
impacts the function of the enzyme in a decisive manner. The
active form of the protease, E, coexists with an inactive form, E*,
that is distinct from the zymogen conformation (9). The E*
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form features a collapse of the 215–217 !-strand into the
active site and a flip of the peptide bond between residues
Glu192 and Gly193 that disrupts the oxyanion hole. Importantly, the ion pair between Ile16 and Asp194 remains intact,
suggesting that E* is not equivalent to the zymogen form of
the protease and that the E*-E equilibrium is established
after the conversion from the zymogen form has taken place.
Indeed, existing structures of the zymogen forms of trypsin
(10), chymotrypsin (11), and chymase (12) feature a broken
Ile16–Asp194 ion pair but no collapse of the 215–217
!-strand. Stopped-flow experiments show that the E*-E conversion takes place on a time scale of !10 ms (5), as opposed
to the much longer (100 –1000 ms) time scale required for
the zymogen-protease conversion (13, 14).
The E* form is not a peculiarity of thrombin. The collapse
of the 215–217 !-strand into the active site is observed in the
inactive form of "I-tryptase (15), the high temperature
requirement-like protease (16), complement factor D (17),
granzyme K (18), hepatocyte growth factor activator (19),
prostate kallikrein (20), and prostasin (21). A disrupted
oxyanion hole is observed in complement factor B (22) and
the arterivirus protease Nsp4 (23). The most likely explanation for the widespread occurrence of inactive conformations of trypsin-like proteases is that the E*-E equilibrium is
a basic property of the trypsin fold that fine tunes activity
and specificity once the zymogen 3 protease conversion has
taken place (9).
The new paradigm established by the E*-E equilibrium has
obvious physiological relevance. In the case of complement
factors, kallikreins, tryptase, and some coagulation factors
must be kept to a minimum until binding of a trigger factor
ensues. Stabilization of E* may afford a resting state of the
protease waiting for action, as seen for other systems (24 –
28). For example, factor B is mostly inactive until binding of
complement factor C3 unleashes catalytic activity at the site
where amplification of C3 activation is most needed prior to
formation of the membrane attack complex (29). Indeed, the
crystal structure of factor B reveals a conformation with the
oxyanion hole disrupted by a flip of the 192–193 peptide
bond (22), as observed in the E* form of thrombin (6, 7).
The allosteric equilibrium as shown in Scheme 1,
k1
E* |
-0 E
k "1
SCHEME 1
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Previous studies have shown that deletion of nine residues in
the autolysis loop of thrombin produces a mutant with an anticoagulant propensity of potential clinical relevance, but the
molecular origin of the effect has remained unresolved. The
x-ray crystal structure of this mutant solved in the free form at
1.55 Å resolution reveals an inactive conformation that is practically identical (root mean square deviation of 0.154 Å) to the
recently identified E* form. The side chain of Trp215 collapses
into the active site by shifting >10 Å from its position in the
active E form, and the oxyanion hole is disrupted by a flip of the
Glu192–Gly193 peptide bond. This finding confirms the existence of the inactive form E* in essentially the same incarnation
as first identified in the structure of the thrombin mutant
D102N. In addition, it demonstrates that the anticoagulant profile often caused by a mutation of the thrombin scaffold finds its
likely molecular origin in the stabilization of the inactive E*
form that is selectively shifted to the active E form upon thrombomodulin and protein C binding.

Anticoagulant Thrombin
involves the rates for the E* 3 E transition, k1, and backward,
k"1, that define the equilibrium constant r # k"1/k1 # [E*]/[E]
(5). The value of kcat/Km for an enzyme undergoing the E*-E
equilibrium is as shown in Equation 1 (30),
sE
k cat
#s#
Km
1 $ r

(Eq. 1)

where sE is the value of s for the E form, and obviously sE* # 0.
Likewise, the binding of an inhibitor to the enzyme undergoing
the E*-E equilibrium is shown in Equation 2,
K#

KE
1 $ r

(Eq. 2)

MATERIALS AND METHODS
The human thrombin mutant $146 –149e was constructed,
expressed, and purified to homogeneity as reported elsewhere
(32, 35, 36), using the QuikChange site-directed mutagenesis
kit from Stratagene (La Jolla, CA) in an HPC4-modified pNUT
expression vector containing the human prethrombin-1 gene.
Values of s # kcat/Kmfor the hydrolysis of the chromogenic
substrates H-D-Phe-Gly-Arg-p-nitroanilide, H-D-Phe-ProPhe-p-nitroanilide, H-D-Phe-Pro-Lys-p-nitroanilide, and H-DPhe-Pro-Arg-p-nitroanilide (FPR),2 the release of fibrinopeptide A from fibrinogen, cleavage of the protease-activated
receptors PAR1, PAR3, and PAR4, and activation of protein C
in the absence or presence of 100 nM thrombomodulin and 5
mM CaCl2 were determined as reported elsewhere (32, 37, 38)
under physiological experimental conditions of 5 mM Tris, 0.1%
PEG8000, 145 mM NaCl, pH 7.4, at 37 °C.
Binding of the active site inhibitor argatroban (39) was studied directly by isothermal titration calorimetry under experimental conditions of 5 mM Tris, 0.1% PEG8000, 145 mM NaCl,
pH 7.4, at 37 °C, using an iTC200 calorimeter (MicroCal Inc.
Northampton, MA) with the sample cell containing thrombin
and the syringe injecting argatroban. The sample volume for
iTC200 is 204.6 %l and the total volume of injected ligand is 39.7
%l. The thermal equilibration step at 37 °C, was followed by an
initial 60-s delay step and subsequently an initial 0.2-%l injec2

The abbreviations used are: FPR, H-D-Phe-Pro-Arg-p-nitroanilide; r.m.s.d.,
root mean square deviation; PC, protein C; TM, thrombomodulin; PAR, protease-activated receptor.
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RESULTS
Once generated in the blood from its inactive precursor prothrombin, thrombin acts as a procoagulant when it converts
fibrinogen into an insoluble fibrin clot (45) and acts as a prothrombotic when it cleaves protease-activated receptors
(PARs) (46, 47). However, upon interaction with the endothelial cell receptor thrombomodulin, thrombin loses both procoagulant and prothrombotic functions and increases its activity
%1,000-fold toward the anticoagulant protein C (48). A thrombin mutant stabilized in the E* form would have little or no
activity toward physiological substrates. If this mutant could be
converted to the E form upon binding of thrombomodulin,
then a selective anticoagulant response would be elicited upon
activation of protein C in the vascular endothelium where
thrombomodulin is present.
The mutant $146 –149e carries a deletion of the nine residues 146ETWTANVGK149e in the autolysis loop and was
originally constructed to assess the role of this highly flexi-
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where KE is the value of the equilibrium association constant K
for the E form, and KE* # 0. As the value of r increases upon
stabilization of E*, the values of s and K in Equations 1 and 2
decrease without limits. Hence, stabilization of E* has the
potential to completely abrogate substrate hydrolysis (s 3 0) or
inhibitor binding (K 3 0). However, binding of a suitable cofactor could restore activity by triggering the E* 3 E transition.
This suggests a simple explanation for the anticoagulant profile
observed in a number of thrombin mutants that have poor
activity toward all physiological substrates but retain activity
toward the anticoagulant protein C in the presence of the cofactor thrombomodulin (31–34). Here we report evidence that
stabilization of E* provides a molecular mechanism to turn
thrombin into an anticoagulant.

tion. Typically, 19 serial injections of 2 %l and 1 last injection of
1.5 %l of ligand were performed at an interval of 180 s. The
stirring speed was maintained at 1000 rpm, and the reference
power was kept constant at 5 %cal/s. The heat associated with
each injection of ligand was integrated and plotted against the
molar ratio of ligand to macromolecule. Thermodynamic
parameters were extracted from a curve fit to the data using the
software (Origin 7.0) provided by MicroCal according to a onesite binding model. Experiments were performed in triplicate
with excellent reproducibility (!10% variation in thermodynamic parameters).
Crystals of human thrombin $146 –149e were obtained
using the hanging drop vapor-diffusion method. A solution of
$146 –149e (8 mg/ml in 1 %l) in 50 mM NaCl, 20 mM Tris, pH
7.5, was mixed with an equal volume reservoir solution containing 20% PEG20000 and 100 mM Tris, pH 8.5, at 25 °C. Crystals
were tetragonal, space group P43, with unit cell parameters a #
b # 58.2 Å, c # 119.6 Å, and contained one molecule in the
asymmetric unit. Crystals were flash-frozen in liquid nitrogen
after soaking in artificial mother liquor containing 15% (v/v)
glycerol. X-ray diffraction data were recorded on an ADSC
Quantum 315 CCD at beamline 14-BM-C at BIOCARS
(Argonne, IL). One pass of 150° with steps of 0.5° was collected
and processed to 1.55 Å resolution. Integration and scaling of
diffraction data were carried out with the HKL-2000 package
(40). The structure was solved by molecular replacement using
the CCP4 suite (41) and Protein Data Bank accession code
2GP9 (7) as a search model. Rounds of positional and isotropic
temperature factor refinement in REFMAC (42) were alternated with model building in COOT (43). After most of the
model was found, TLS tensors modeling rigid-body anisotropic
temperature factors were calculated and applied to the model
using REFMAC. This was alternated with more model building
in COOT until the final model was produced. Ramachandran
plots were calculated using PROCHECK (44). Statistics for data
collection and refinement are summarized in Table 1. Coordinates of the structure of the human thrombin mutant $146 –
149e have been deposited to the Protein Data Bank (accession
code 3GIC).

Anticoagulant Thrombin
TABLE 1
Crystallographic data for the thrombin mutant !146 –149e (Protein
Data Bank code 3GIC)
Data collection
Wavelength
Space group
Unit cell dimension
Molecules/asymmetric unit
Resolution range
Observations
Unique observations
Completeness
Rsym (%)
I/&(I)

a
b

40.0–1.55 Å
%0
0.188, 0.224
51,479/2747
2295
257
0.012 Å
1.4°
0.86/0.67/2.21
18.6 Å2
28.6 Å2

Ramachandran plot
Most favored
Generously allowed
Disallowed

98.3%
1.3%
0.4%

Root mean square deviations from ideal bond lengths and angles and r.m.s.d.
values in B-factors of bonded atoms are shown.
mm indicates main chain-main chain; ms indicates main chain-side chain; and ss
indicates side chain-side chain.

ble domain in thrombin function (49). The sequence
149a
ANVGK149e is not present in trypsin and chymotrypsin and
can be deleted without functional consequences (49). Also,
swapping the entire 146ETWTANVGK149e sequence of thrombin with the 146SSGT149 sequence of trypsin (50) or deleting the
146
ETW148 sequence (51) produces perturbations of function
that are recapitulated by the single mutations E146A and
R221aA (32, 35). Residue Glu146 makes an important ion pair
interaction with Arg221a in the adjacent 220-loop in the E form
but not in the E* form (6, 7, 35). The entire autolysis loop likely
participates in the long range communication seen in the E*-E
equilibrium (6) between the 220-loop, the active site, and
exosite I where thrombomodulin binds (8). Deletion of the
entire sequence 146ETWTANVGK149e in the $146 –149e
mutant causes a significant loss of activity toward chromogenic
and physiological substrates, but binding of thrombomodulin
almost completely restores activity toward the anticoagulant
protein C (Fig. 1). Importantly, thrombomodulin has only a
modest effect on the hydrolysis of a chromogenic substrate
(Fig. 1), as already documented for other anticoagulant
thrombin mutants (52) and wild type (53). These properties
suggest that the $146 –149e mutation shifts the E*-E equilibrium of thrombin in favor of E*, and thrombomodulin in
complex with protein C can switch the mutant back into the
active conformation E.
Evidence that the thrombin mutant $146 –149e is stabilized in the E* form in solution comes from inspection of the
values of kcat/Km for chromogenic and natural substrates.
The data in Fig. 1 reveal a remarkable similarity in the loss of
activity toward fibrinogen, PAR1, PAR3, and protein C for
the $146 –149e mutant compared with wild type. Likewise, a
comparable loss of activity is observed toward several chro-
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FIGURE 1. Functional properties of the thrombin mutant !146 –149e.
Shown are the values of s # kcat/Km for the hydrolysis of chromogenic substrates H-D-Phe-Gly-Arg-p-nitroanilide (FGR), H-D-Phe-Pro-Phe-p-nitroanilide
(FPF), H-D-Phe-Pro-Lys-p-nitroanilide (FPK), and FPR, fibrinogen (FpA), PAR1,
PAR3, PAR4, protein C (PC), and protein C (PC&TM) or FPR (S&TM) in the
presence of 100 nM thrombomodulin and 5 mM CaCl2 for wild-type (swt) relative to the thrombin mutant $146 –149e (smut). All substrates, except PAR4,
experience a loss of activity that equals 2.30 log units (solid line) with a standard deviation of 0.09 log units (broken lines). This supports perturbation of the
E*-E equilibrium in favor of the inactive form E* (see Equations 1 and 3 in the
text). The larger loss for PAR4 (%4 S.D. compared with the other substrates) is
likely due to direct interaction of the substrate with residues of the autolysis
loop (55) that are missing in the $146 –149e mutant. In the presence of
thrombomodulin, the mutant experiences only a 2-fold drop in activity
toward protein C compared with wild type. However, thrombomodulin binding alone does not restore activity toward the chromogenic substrate FPR.
Experimental conditions are as follows: 5 mM Tris, 0.1% PEG8000, 145 mM
NaCl, pH 7.4, at 37 °C. The values of swt are as follows: 0.52 ' 0.05 %M"1 s"1
H-D-Phe-Gly-Arg-p-nitroanilide (FGR), 0.28 ' 0.03 %M"1 s"1 H-D-Phe-Pro-Glyp-nitroanilide (FGF), 4.2 ' 0.2 %M"1s"1 H-D-Phe-Pro-Gly-p-nitroanilide (FGK),
37 ' 1 %M"1 s"1 H-D-Phe-Pro-Arg-p-nitroanilide (FPR), 17 ' 1 %M"1 s"1 fibrinogen
(FpA), 39 ' 1 %M"1s"1 PAR1, 0.35 ' 0.02 %M"1 s"1 PAR3, 0.34 ' 0.01
"1
%M s"1 PAR4, 59 ' 3 M"1 s"1 PC, 0.22 ' 0.01 %M"1s"1 PC&TM, 64 ' 2
%M"1s"1 S&TM.

mogenic substrates bearing replacements at the P1 or P2
positions (54). On the average, the loss is about 200-fold. For
a mutation that selectively shifts the E*-E equilibrium in
favor of E*, without introducing additional effects on substrate or inhibitor recognition, the values of s and K in Equations 1–2 must decrease by the same amount. Specifically,
the ratio shown in Equation 3 between the wild-type (WT)
and mutant values of s and K must be the same for all substrates and inhibitors.
s WT KWT 1 $ rmut
#
#
smut Kmut 1 $ rWT

(Eq. 3)

The data in Fig. 1 are consistent with the prediction from Equation 3. Perturbation of PAR4 recognition is significantly more
pronounced compared with all other substrates, but this is consistent with the direct interactions that this substrate makes
with residues of the autolysis loop (55). Further support for
stabilization of E* in the $146 –149e mutant comes from calorimetric measurements of the binding of the inhibitor argatroban (39) to the active site. The value of K (see Equation 2) drops
135-fold in the mutant compared with wild type (Fig. 2), as
expected from Equation 3.
Addition of thrombomodulin restores activity of the mutant
toward protein C (Fig. 1), indicating that although the mutation
stabilizes E*, the active form E is still present in solution and can
be populated for protein C activation in the presence of cofac-
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Refinement
Resolution
!F!/&(!F!)
Rcryst, Rfree
Reflections (working/test)
Protein atoms
Solvent molecules
r.m.s.d. bond lengthsa
r.m.s.d. anglesa
r.m.s.d. $B (Å2) (mm/ms/ss)b
(B) protein
(B) solvent

0.9 Å
P43
a # b # 58.23, c # 119.56 Å
1
40.0–1.55 Å
220,618
54,240
94.3% (76.1%)
3.7% (27.9%)
27.7 (2.3)
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FIGURE 3. Ribbon representation of the structure of the thrombin mutant
!146 –149e (gold) overlaid with the structure of thrombin in the E conformation (35) (cyan). The newly formed peptide bond between Lys145 and Gly150
is indicated in red in the shortened autolysis loop of $146 –149e (see also Fig. 4),
and the loop in the E conformation is not visible between residues Trp148 and
Lys149e. The 215–217 !-strand in the mutant collapses into the primary specificity
pocket (red open arrowheads), with the side chain of Trp215 (stick model) repositioned into the active site (residues of the catalytic triad His57, Asp102, and Ser195
shown as stick models) in hydrophobic interaction with Trp60d, Tyr60a, Leu99, and
His57. This represents a drastic change (r.m.s.d. 0.384 Å) from the conformation of
E where the side chain of Trp215 is positioned 10.5 Å away and leaves the active
site accessible to substrate. The conformation of $146 –149e is remarkably similar (r.m.s.d. 0.154 Å) to that of E* determined recently (6, 7).
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DISCUSSION
The new paradigm emerged from analysis of recent crystal
structures of trypsin-like proteases (6, 7, 15–23) supports the
existence of the E*-E equilibrium as a critical feature of the
trypsin fold (9). This allosteric equilibrium explains several
important aspects of protease biology. For proteases that are
poorly active until interaction with a cofactor, as observed for
some clotting and complement factors (29), the onset of catalytic activity can be attributed to the E* 3 E conversion. The E*
form acts in this case as a resting state for the enzyme and a
spring-loaded mechanism that can be turned on when required
JOURNAL OF BIOLOGICAL CHEMISTRY
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tor. Evidence that binding to exosite
I, the major thrombin epitope for
thrombomodulin recognition (56,
57), can convert E* to E has been
provided recently by the structure
of the thrombin mutant D102N
bound to a fragment of the platelet
receptor PAR1 (6). Therefore, the
thrombin mutant $146 –149e likely
functions as an allosteric switch stabilized into the inactive form E*
until the combined binding of
thrombomodulin and protein C
shifts E* to E and restores activity.
To gain direct information on the
conformational properties of the
$146 –149e mutant, its crystal
structure was solved in the free form
at 1.55 Å resolution. Consistent
with the functional data, the mutant
assumes a collapsed conformation
that is practically identical (r.m.s.d.
FIGURE 2. Argatroban binding to thrombin wild type (left) and !146 –149e (right) measured by isothermal
titration calorimetry.The top panel shows the heat exchanged in each individual titration for the thrombin sample 0.154 Å) to the E* form identified
(bottom trace) and the argatroban buffer control (top trace). The bottom panel is the integration of the data to yield recently from the structure of the
the overall heat exchanged as a function of the ligand/protein molar ratio. Experimental conditions are 5 mM Tris,
0.1% polyethylene glycol, 145 mM NaCl, pH 7.4, 37 °C. The enzyme and argatroban concentrations are as follows: thrombin mutant D102N (6, 7). The
13.44 and 140 %M (thrombin wild type); 52.5 and 777 %M ($146 –149e). Titration curves were fit using the Origin $146 –149e mutant folds in a selfsoftware of the iTC200, with best fit parameter values as follows: thrombin wild type,K # 1.0 ' 0.1 108 M"1, $G # inhibited conformation (Fig. 3) due
"11.3 ' 0.1 kcal/mol, $H # "15.2 ' 0.1 kcal/mol, and T$S # "3.9 ' 0.1 kcal/mol; $146 –149e, K # 7.4 ' 0.4 105
"1
to a collapse of the 215–217
M , $G # "8.3 ' 0.1 kcal/mol, $H # "13.8 ' 0.1 kcal/mol, and T$S # "5.5 ' 0.1 kcal/mol. The value of the
stoichiometric constant N was 1.01 ' 0.01 for thrombin wild type and the $146 –149e mutant.
!-strand into the active site that
moves the indole ring of Trp215 %10
Å to engage the catalytic His57 on the opposite side of the active
site cleft (Fig. 4). The drastic rearrangement of the 215–217
!-strand propagates the perturbation up to the peptide bond
between Glu192 and Gly193 that is flipped relative to the conformation of the E form (7) and destroys the architecture of the
oxyanion hole (Fig. 4). These significant structural changes
occur away from the site of mutation in the autolysis loop,
where the shortened sequence 144LKGQ151 shows Lys145 connected directly to Gly150 (Fig. 4). Hence, the thrombin mutants
D102N and $146 –149e crystallize in the same E* form, notwithstanding differences in sequence and crystallization conditions. The inactive form E* is therefore a genuine conformation
of thrombin accessible to the enzyme in addition to its active
form E (9, 35). The E* form is stabilized by mutations that compromise activity of the enzyme and is selectively converted to
the active E form under suitable conditions.

Anticoagulant Thrombin

by the biological context. The E*-E equilibrium also provides
context to interpret the effect of mutations associated with loss
of biological activity in highly active proteases. In some cases, as
documented by thrombin (8, 58), the molecular origin of the
effect is unclear because the mutation does not affect residues
in direct contact with substrate. Stabilization of E* through
molecular conduits not necessarily involved in substrate recognition may offer a plausible explanation.
The allosteric E*-E equilibrium has far reaching implications
for protein engineering. Stabilization of E* by selected mutations, coupled with a transition to E triggered by suitable cofactors, may result in expression of protease activity on demand in
a biological context. Thrombin exists predominantly in the E
form, which functions as an ensemble partitioned between
Na&-free and Na&-bound conformations (5, 8) because of the
extremely fast rates of binding and dissociation of Na& with the
enzyme (59). However, a thrombin mutant stabilized in the E*
form that converts to E upon interaction with thrombomodulin
and protein C would be an anticoagulant of potential clinical
relevance. Such mutant would show little or no activity toward
fibrinogen and PAR1 but would retain activity toward protein
C. A number of thrombin mutants have been reported with an
altered specificity that favors protein C activation over fibrinogen cleavage (31–34, 49, 60, 61). Among these mutants, E217K
and W215A/E217A are effective as anticoagulants and antithrombotics in non-human primates (33, 34, 62, 63) and have
been crystallized at 2.5–2.8 Å resolution (52, 64). The structures show a partial collapse of the 215–217 !-strand and disruption of the oxyanion hole that resembles the conformation
of E* (7). It is possible that these mutants are stabilized in an
E*-like form, but it is equally possible that the perturbed structures are the result of the mutations introduced at residues on
the critical 215–217 !-strand. Substantial crystallographic
packing interactions especially evident in the E217K mutant
also bias the conformation, unlike the structures of the mutants
D102N (7) and $146 –149e reported here. Additional struc-
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FIGURE 4. Left, details of the collapse of Trp215 into the active site and disruption of the oxyanion hole in the thrombin mutant $146 –149e (CPK, yellow)
are shown. The conformation of the same residues in the E form is shown by
comparison (CPK, cyan). The peptide bond between Glu192 and Gly193 is
flipped in the $146 –149e mutant (red open arrowhead), as seen in the E* form
(6, 7, 9), causing disruption of the oxyanion hole contributed by the N atoms
of Gly193 and Ser195. The 2Fo " Fc electron density map (green mesh) is contoured at 2.0&. Right, deletion of residues 146ETWTANVGK149e in the autolysis
loop of the $146 –149e mutant results in a new peptide bond connection
between Lys145 and Gly150 (CPK, yellow). The autolysis loop is rarely seen in its
entirety in thrombin structures, and considerable disorder remains in the
mutant $146 –149e where the sequence 144LKGQ151 must be contoured at
0.5& in the 2Fo " Fc electron density map (green mesh).

tural work is necessary to validate the collapsed conformations
of E217K and W215A/E217A.
The mutant $146 –149e was previously identified for its significant anticoagulant profile (49) and carries a deletion of nine
residues in the highly disordered autolysis loop, whose role in
the function of the enzyme remains elusive. Importantly, residues of the autolysis loop are separate from the 215–217
!-strand or the oxyanion hole that undergoes substantial rearrangement in the E*-E transition (6, 7). Yet the mutant $146 –
149e crystallizes in a collapsed conformation that is practically
identical (r.m.s.d. 0.154 Å) to the E* form identified recently (6,
7). This result is notable for two reasons. First, it confirms the
existence of the inactive form E* in essentially the same incarnation as first identified in the structure of the thrombin
mutant D102N under different crystallization conditions. Second, it provides proof of principle that the anticoagulant profile
often caused by a mutation of the thrombin scaffold finds its
likely molecular origin into stabilization of the inactive E* form.
The mutant $146 –149e was previously reported to feature
reduced Na& affinity (49), which supports the conclusion that
its active E form is essentially Na&-free. This confirms the tenet
that abrogation of the procoagulant effect of Na& (32, 65) is
necessary to switch thrombin into an anticoagulant.
There is no contradiction between the modest effect of
thrombomodulin on chromogenic substrate hydrolysis (Fig. 1)
and structural evidence of the E* to E transition upon exosite I
binding (6). Crystallographic evidence that the D102N mutant
assumes the E* form when free and the E form when bound to
exosite I does not imply an all-or-none distribution of E* and E
in solution. In fact, a significant fraction of D102N does exist in
the E form in solution (7), but this conformation is not favored
under the crystallization conditions so far explored (7). Thermodynamic principles (66, 67) establish that an allosteric effector can only shift the E*-E equilibrium in favor of E by an
amount equal to the ratio of affinities of the two forms. Because
exosite I, unlike the active site, is similarly accessible in the E*
and E form (6 – 8, 35), binding of thrombomodulin to the two
forms cannot result in extreme perturbations of the E*-E equilibrium. Hence, when the equilibrium is shifted drastically in
favor of E*, as seen for the $146 –149e mutant but not the
D102N mutant, binding of thrombomodulin is insufficient to
populate significantly the active form E. On the other hand, the
combined action of protein C and thrombomodulin may have a
more profound effect on the E*-E equilibrium by accessing
additional regions of the thrombin surface beyond exosite I
(57), thereby ensuring almost complete restoration of activity.
Elucidation of the molecular mechanism underscoring the
anticoagulant profile of thrombin mutants like $146 –149e
provides new impetus to the effort of rationally engineering
thrombin mutants with exclusive activity toward protein C for
clinical applications. The molecular underpinnings of the E*-E
equilibrium have been revealed by structural biology (6), along
with precise targets for mutagenesis aimed at stabilizing the E*
form. An exclusive protein C activator would have several
advantages compared with the direct administration of activated protein C currently marketed for the treatment of sepsis
(68). Activated protein C acts as an anticoagulant when it inactivates clotting factor Va with the assistance of the cofactor

Anticoagulant Thrombin

REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.

Page, M. J., and Di Cera, E. (2008) Cell. Mol. Life Sci. 65, 1220 –1236
Bode, W., and Huber, R. (1976) FEBS Lett. 68, 231–236
Hedstrom, L. (2002) Chem. Rev. 102, 4501– 4524
Bode, W., Schwager, P., and Huber, R. (1978) J. Mol. Biol. 118, 99 –112
Bah, A., Garvey, L. C., Ge, J., and Di Cera, E. (2006) J. Biol. Chem. 281,
40049 – 40056
Gandhi, P. S., Chen, Z., Mathews, F. S., and Di Cera, E. (2008) Proc. Natl.
Acad. Sci. U.S.A. 105, 1832–1837
Pineda, A. O., Chen, Z. W., Bah, A., Garvey, L. C., Mathews, F. S., and Di
Cera, E. (2006) J. Biol. Chem. 281, 32922–32928
Di Cera, E. (2008) Mol. Aspects Med. 29, 203–254
Di Cera, E. (2009) IUBMB Life 61, 510 –515
Fehlhammer, H., Bode, W., and Huber, R. (1977) J. Mol. Biol. 111,
415– 438
Wang, D., Bode, W., and Huber, R. (1985) J. Mol. Biol. 185, 595– 624
Reiling, K. K., Krucinski, J., Miercke, L. J., Raymond, W. W., Caughey,
G. H., and Stroud, R. M. (2003) Biochemistry 42, 2616 –2624
Fersht, A. R. (1972) J. Mol. Biol. 64, 497–509
Fersht, A. R., and Requena, Y. (1971) J. Mol. Biol. 60, 279 –290
Rohr, K. B., Selwood, T., Marquardt, U., Huber, R., Schechter, N. M., Bode,
W., and Than, M. E. (2006) J. Mol. Biol. 357, 195–209
Krojer, T., Garrido-Franco, M., Huber, R., Ehrmann, M., and Clausen, T.
(2002) Nature 416, 455– 459
Jing, H., Babu, Y. S., Moore, D., Kilpatrick, J. M., Liu, X. Y., Volanakis, J. E.,
and Narayana, S. V. (1998) J. Mol. Biol. 282, 1061–1081
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and Gibbs, C. S. (1996) Biochemistry 35, 16449 –16457
35. Pineda, A. O., Carrell, C. J., Bush, L. A., Prasad, S., Caccia, S., Chen, Z. W.,
Mathews, F. S., and Di Cera, E. (2004) J. Biol. Chem. 279, 31842–31853
36. Prasad, S., Wright, K. J., Banerjee Roy, D., Bush, L. A., Cantwell, A. M., and
Di Cera, E. (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 13785–13790
37. Ayala, Y. M., Cantwell, A. M., Rose, T., Bush, L. A., Arosio, D., and Di Cera,
E. (2001) Proteins 45, 107–116
38. Vindigni, A., and Di Cera, E. (1996) Biochemistry 35, 4417– 4426
39. Tanaka, K. A., Gruber, A., Szlam, F., Bush, L. A., Hanson, S. R., and Di
Cera, E. (2008) Blood Coagul. Fibrinolysis 19, 465– 468
40. Otwinowski, Z., and Minor, W. (1997) Methods Enzymol. 276, 307–326
41. Bailey, S. (1994) Acta Crystallogr. D Biol. Crystallogr. 50, 760 –763
42. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Acta Crystallogr.
D Biol. Crystallogr. 53, 240 –255
43. Emsley, P., and Cowtan, K. (2004) Acta Crystallogr. D Biol. Crystallogr. 60,
2126 –2132
44. Morris, A. L., MacArthur, M. W., Hutchinson, E. G., and Thornton, J. M.
(1992) Proteins 12, 345–364
45. Spraggon, G., Everse, S. J., and Doolittle, R. F. (1997) Nature 389, 455– 462
46. Coughlin, S. R. (2000) Nature 407, 258 –264
47. Coughlin, S. R. (2005) J. Thromb. Haemost. 3, 1800 –1814
48. Esmon, C. T. (2003) Chest 124, 26S-32S
49. Dang, Q. D., Sabetta, M., and Di Cera, E. (1997) J. Biol. Chem. 272,
19649 –19651
50. DiBella, E. E., and Scheraga, H. A. (1996) Biochemistry 35, 4427– 4433
51. Le Bonniec, B. F., Guinto, E. R., and Esmon, C. T. (1992) J. Biol. Chem. 267,
19341–19348
52. Pineda, A. O., Chen, Z. W., Caccia, S., Cantwell, A. M., Savvides, S. N.,
Waksman, G., Mathews, F. S., and Di Cera, E. (2004) J. Biol. Chem. 279,
39824 –39828
53. Vindigni, A., White, C. E., Komives, E. A., and Di Cera, E. (1997) Biochemistry 36, 6674 – 6681
54. Vindigni, A., Dang, Q. D., and Di Cera, E. (1997) Nat. Biotechnol. 15,
891– 895
55. Bah, A., Chen, Z., Bush-Pelc, L. A., Mathews, F. S., and Di Cera, E. (2007)
Proc. Natl. Acad. Sci. U.S.A. 104, 11603–11608
56. Pineda, A. O., Cantwell, A. M., Bush, L. A., Rose, T., and Di Cera, E. (2002)
J. Biol. Chem. 277, 32015–32019
57. Xu, H., Bush, L. A., Pineda, A. O., Caccia, S., and Di Cera, E. (2005) J. Biol.
Chem. 280, 7956 –7961
58. Papaconstantinou, M. E., Bah, A., and Di Cera, E. (2008) Cell. Mol. Life Sci.
65, 1943–1947
59. Gianni, S., Ivarsson, Y., Bah, A., Bush-Pelc, L. A., and Di Cera, E. (2007)
Biophys. Chem. 131, 111–114
60. Griffin, J. H. (1995) Nature 378, 337–338
61. Wu, Q. Y., Sheehan, J. P., Tsiang, M., Lentz, S. R., Birktoft, J. J., and Sadler,
J. E. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 6775– 6779
62. Gruber, A., Cantwell, A. M., Di Cera, E., and Hanson, S. R. (2002) J. Biol.
Chem. 277, 27581–27584
63. Gruber, A., Marzec, U. M., Bush, L., Di Cera, E., Fernández, J. A., Berny,
M. A., Tucker, E. I., McCarty, O. J., Griffin, J. H., and Hanson, S. R. (2007)
Blood 109, 3733–3740
64. Carter, W. J., Myles, T., Gibbs, C. S., Leung, L. L., and Huntington, J. A.
(2004) J. Biol. Chem. 279, 26387–26394
65. Dang, O. D., Vindigni, A., and Di Cera, E. (1995) Proc. Natl. Acad. Sci.

37

JOURNAL OF BIOLOGICAL CHEMISTRY

20039

Downloaded from www.jbc.org at Washington University, on December 9, 2009

protein S and as a cytoprotective agent when it cleaves PAR1
on the surface of endothelial cells with the assistance of
endothelial protein C receptor (69). Importantly, activated
protein C generated in situ with the anticoagulant thrombin
mutant W215A/E217A offers cytoprotective advantages
over activated protein C administered to the circulation (70).
Furthermore, the thrombin mutant W215A/E217A acts as a
potent antithrombotic by blocking the interaction of von
Willebrand factor with the platelet receptor GpIb (71), a
property of which activated protein C is naturally devoid and
that challenges the efficacy of low molecular weight heparins
(63). These intriguing properties of the mutant W215A/
E217A, its well established potency as an anticoagulant in
non-human primates (62, 63) and the current elucidation of
the role of E* in switching thrombin into an anticoagulant,
will facilitate the rational engineering of a thrombin mutant
with exclusive activity toward protein C.

Anticoagulant Thrombin
69. Riewald, M., Petrovan, R. J., Donner, A., Mueller, B. M., and Ruf, W. (2002)
Science 296, 1880 –1882
70. Feistritzer, C., Schuepbach, R. A., Mosnier, L. O., Bush, L. A., Di Cera, E.,
Griffin, J. H., and Riewald, M. (2006) J. Biol. Chem. 281, 20077–20084
71. Berny, M. A., White, T. C., Tucker, E. I., Bush-Pelc, L. A., Di Cera, E.,
Gruber, A., and McCarty, O. J. (2008) Arterioscler. Thromb. Vasc. Biol. 28,
329 –334

20040 JOURNAL OF BIOLOGICAL CHEMISTRY

38

Downloaded from www.jbc.org at Washington University, on December 9, 2009

U.S.A. 92, 5977–5981
66. Wyman, J., and Gill, S. J. (1990) Binding and Linkage, University Science
Books, Mill Valley, CA
67. Di Cera, E. (1995) Thermodynamic Theory of Site-Specific Binding Processes in Biological Macromolecules, Cambridge University Press, Cambridge, UK
68. Levi, M. (2008) Curr. Opin. Hematol. 15, 481– 486

VOLUME 284 • NUMBER 30 • JULY 24, 2009

CHAPTER IV
Investigating the Role of the 145-150 Loop in
Thrombin Allostery

39

In the previous chapters, we demonstrated that human thrombin exists in equilibrium
between inactive E* and active E conformations (1-3), and that deletion of the nine
residues

146

ETWTANVGKG149e from the autolysis loop of human thrombin results in

stabilization of its E* conformation (4). As a result, relative to the wild type enzyme the
activity of Δh146-149e was significantly but identically compromised for all synthetic
and physiological substrates tested including protein C in the absence but not in the
presence of TM. Hence, the TM-PC complex can trigger the E* to E transition and
restore almost full catalytic enhancement of PC activation (4).

Furthermore, structural and kinetic studies have demonstrated that murine thrombin
unlike its human counterpart, lacks Na+ activation (5). However, the enzyme is
functionally stabilized in an E:Na+-like conformation and retains high catalytic activity
towards all its physiological substrates (5, 6). Obviously the thirty-two amino acids that
differ between human and murine thrombin are responsible for these different functional
and structural characteristics between the two enzymes. Six of the thirty-two amino acids
residues are located the autolysis loop. The contribution of these six substitutions in the
differences in Na+ dependent allostery between human and murine thrombin is presently
unknown.

In this chapter, we build upon these data and investigate further what role the length and
amino acid composition of the autolysis loop play in thrombin allostery, particularly its
effects in the E* to E transition and stabilization of E and E:Na+ conformations of
thrombin. Here, we report the generation and characterization of two autolysis loop
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mutants (Table 4.1). The first is Δh145-150 in which 145KG150 were further deleted from
Δh146-149e to generate an eleven residue deletion mutation. In the second mutant,
hm145-150, the human autolysis loop was replaced with the autolysis loop from its
murine counterpart by substituting the six

145

K,

149a

A and

149c

VGKG150 to the

corresponding murine residues (Table 4.1).

Table 4.1 Amino Acid sequence of autolysis loop constructs generated in this chapter

MATERIALS & METHODS
Human thrombin mutants Δh145-150 and hm145-150 (Table 4.1) were constructed,
expressed and characterized as described in chapters 2 and 3.

RESULTS & DISCUSSION

Δh145-150
Mutagenesis studies on the autolysis loop of human thrombin have previously shown that
shorter loops disproportionately compromise the procoagulant/prothrombotic substrates
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compared to the anticoagulant protein C (4, 7, 8). Molecular determinants of this effect
originates from the stabilization of the E* conformation (1). Hence, the Δh145-150
mutant was designed and constructed in anticipation that it will be relatively more
stabilized in the E* conformation compared to Δh146-149e. As a result of deleting two
more residues, we expected to generate a mutant with a significantly more compromised
catalytic activity towards all substrates, but one whose activation of protein C in the
presence of TM will be comparable to the hwt enzyme as observed in Δh146-149e. When
successful, these properties will increase its anticoagulant and antithrombotic profile
relative to Δh146-149e, thereby making it a better therapeutic agent.

The functional properties of Δh145-150 were tested under physiological conditions
against a diverse set of chromogenic and macromolecular substrates (Figure 4.1). The
value of kcat/KM for substrate hydrolysis is significantly affected relative to the wt for all
substrates but the extent of the effect varies with each substrate. More importantly, the
activation of protein C is not restored relative to the wt in the presence of TM resulting in
no gain in the anticoagulant profile. This observation is directly contrary to what will be
expected from an exclusive E* stabilization in which we would observe a similar effect
on kcat/KM irrespective of substrate and restoration of protein C activation in the presence
of TM, as demonstrated for Δh146-149e in chapter 3. Several plausible explanations can
account for this unexpected observation including; the longer deletion (i) affects the E* to
E transition and/or (ii) interferes with the intrinsic catalytic properties of the enzyme.
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To investigate the molecular origins of its observed kinetic profile, crystals of Δh145-150
were grown in the presence and absence of Na+. Structure of the mutant in the absence of
Na+ was obtained in the E* conformation of thrombin. All the structural signatures of E*
were observed (Figure 4.2 and Figure 4.3); abrogation of the Na+ binding site, collapse of
the 215-217 β-strand into the active site and a disruption of oxyanion hole. The structure
of Δh145-150 in the absence of Na+ is practically similar to the E* form of Δh146-149e.

Figure 4.1. Functional properties of the thrombin mutant Δh145-150. Shown are the values
of s=k /K for the hydrolysis of chromogenic substrates FGR, FPK and FPR, fibrinogen (FpA),
PAR1, PAR3, PAR4, protein C (PC) and protein C (PC+TM) in the presence of 100 nM
thrombomodulin and 5 mM CaCl for the thrombin mutant Δh145-150 (smut) relative to wildtype (swt). Each substrate experiences a different loss of activity that cannot be reconciled with an
exclusive perturbation of the E*-E equilibrium in favor of the inactive form E*, as recently
reported for the Δ146-149e mutant (chapter 3). Experimental conditions are: 5 mM Tris, 0.1%
PEG8000, 145 mM NaCl, pH 7.4 at 37 °C. The values of swt are: 0.52±0.05 µM s (FGR),
4.2±0.2 µM s (FPK), 37±1 µM s (FPR), 17±1 µM s (FpA), 39±1 µM s (PAR1), 0.35±0.02
µM s (PAR3), 0.34±0.01 µM s (PAR4), 59±3 M-1s-1 (PC), 0.22±0.01 µM s (PC+TM).
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On the other hand, in the presence of Na+, Δh145-150 is stabilized in the canonical E:
Na+ conformation, but with one notable exception. Although the collapse of the 215-217
β-strand into the active site is corrected with Trp-215 moving back into the position
observed in the E: Na+ form of wt, the disruption of the of the oxyanion hole is not
restored to its proper architecture. Collectively, these functional and structural data
indicate that in addition to the E* to E equilibrium pertubation, the intrinsic catalytic
properties of the enzyme are affected by the longer deletion mutation.

The kinetic and structural properties of Δh145-150 are not unique to this mutant,
however. Similar properties were recently observed in the N143P mutant of human
thrombin. Each substrate analyzed was perturbed to a different extent, an E*
conformation was crystallographically observed in the absence of Na+ and the Na+-bound
structure also features a disruption of the oxyanion hole. A proper architecture of the
oxyanion hole is required to stabilize the tetrahedral intermediate during substrate
hydrolysis and is directly under the control of the bound Na+ (3, 4).

Comparison between the N143P and Δh145-150 Na+-bound conformations indicate that
in both structures, despite the different mutations, a highly conserved H-bond between
the carbonyl O atom of residue 192 and the backbone N atom of residue 143 on the
adjacent β-strand is broken (Figure 4.3). When this important H-bond interaction is lost,
the 192-193 peptide bond flips and the oxyanion hole pocket is disrupted. As in the case
of the N143P mutant, Na+ has lost the ability to regulate the architecture of the oxyanion
hole in Δh145-150, thereby affecting the intrinsic kinetic properties of both enzymes.
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Figure 4.2 Crystal Structure of Δh145-150 in the E* and E: Na+ forms. A. Structural
alignment of Δh145-150 E* and Δh145-150 E:Na+ in cartoon representation. Occlusion of the
active site cleft in the E* by the 215-217 B-strand (blue) compared to E: Na+ conformation (red).
B and C are surface representation of Δh145-150 E* and E: Na+ structures respectively. Note how
the catalytic residues and active site cleft are completely occluded in B and accessible in C.
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Figure 4.3 Achitecture of the oxyanion hole in (A) Δh145-150 E* (B) hWT and (C) Δh145150 E:Na+. Conserved H-bond between carbonyl O atom of Glu-192 and backbone N atom of
143 is broken in Δh145-150 E* and Δh145-150 E: Na+ but not in hWT. As a result, the 192-193
peptide bond flips and the oxyanion hole is disrupted.

Mutants that are stabilized in the E* confirmation and whose catalytic properties
are significantly compromised have great potential application for in vivo studies. Such
mutants can complement functional studies of anticoagulant and antithrombotic mutants
such as W215A/E217A (WE). For instance, Berny et. al. have shown that although WE
cannot activate platelets, it can interact with platelets through GPIb and disrupts the
GPIb-dependent binding to von Willebrand factor-collagen under shear (9). Wt or the
catalytically inactive S195A mutant cannot produce these effects, indicating that some
unique feature (s) of WE is responsible for its antagonistic properties against GPIb. To
date, the molecular basis of this antithrombotic property of WE is unknown. However,
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the E* features, the specific mutation effects or some yet unknown characteristic of WE
is definitely causing this anomalous and extraordinary interaction of WE with GPIb.
Therefore, Δh145-150 can be an excellent control to test the hypothesis that WE’s E*
nature is responsible for antagonizing GPIb.

hm145-150
Previous attempts to mimic the activating effects of Na+ in human thrombin or other type
II- Na+ activating enzymes were moderately successful as they generally results in poor
activity enzymes both in the presence and absence of Na+ (6, 10, 11). However, structural
and kinetic studies reveal that murine thrombin has successfully mimicked the E:Na+
conformation of human thrombin (5). The origin of this remarkable property is not fully
understood as the swapping of the entire Na+ binding loops of murine thrombin into the
human enzyme did not result in a high activity Na+ independent enzyme (6).

However, biochemical studies have shown that one of the effects of Na+ binding to
human thrombin is to stabilize the highly flexible autolysis loop (12), which in the
murine enzyme is intrinsically stable due to intra-loop interactions (13, 14). These
interactions originate from six critical amino acid substitutions that differ between the
autolysis loop of murine and human thrombin (Table 4.1). The contribution of amino acid
composition of the autolysis loop in the Na+ dependent allostery of human thrombin has
not been previously investigated although this loop is not highly conserved in thrombin
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molecules from different species (15). In this section, we directly addressed the role of
the autolysis loop in the different Na+ response between murine and human thrombin.

When the human autolysis loop is replaced with its murine counterpart, the catalytic
properties of the mutant are intermediate between those of the two enzymes. In the
absence of Na+, the activity of the hm145-150 is higher than that of human but less than
murine thrombin, while the converse is true in the presence of Na+. Figure 4.4 shows that
kcat/KM of hm145-150 for FPR hydrolysis was enhanced 7-fold relative to hwt thrombin
in the absence of Na+, and that the effect of Na+ on the kinetic properties of the mutant
was drastically reduced as demonstrated by only a 3-fold compared to a 27-fold
enhancement in kcat/KM in hm145-150 and hWT respectively. Similar results were
obtained for other chromogenic and macromolecular substrates tested. These data
indicate that most of the Na+ independent high activity effect of murine thrombin and low
activity of slow form of human thrombin originate from the amino acid composition of
their respective autolysis loops.

Furthermore, kinetics and thermodynamic of Na+ binding studies were performed to
assess the effect of the autolysis loop swap on the Na+ dependent allostery. Na+ binding
to hWT thrombin is biphasic in kinetics and is characterized by large enthalpy and
entropy change of -22 kcal/mol and -64 cal/mol/K respectively (1, 10, 16). A major
contribution to these thermodynamic parameters originate from the six ligating
interactions involving Na+, and the uptake and re-ordering of water molecules that
transmit Na+ binding through the water channel to activity in the active site(17). In
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addition, Na+ binding is accompanied by a large intrinsic heat capacity change of -500
cal/mol/K, but the molecular origins of this effect have not been uncovered so far (16)

Figure 4.4. Effect of Na+ on FPR substrate hydrolysis. Shown are the values of s=k /K for the
hydrolysis of chromogenic substrate FPR in the presence or absence of Na + by human wild type
(hWT), hm145-150 and murine wild thrombin (mWT). Experimental conditions are: 5 mM Tris,
0.1% PEG8000, 200 mM NaCl or ChCl, pH 8 at 25°C.
cat

M

Stopped flow fluorescence measurements of Na+ binding to hm145-150 shows a similar
biphasic binding mechanism as observed in the hwt, indicating the presence of E*, E and
E: Na+ forms (Figure 4.6). However, as highlighted from the amplitude of the slow phase
in Figure 4.6 and data fitting analysis, in hm145-150, the E* to E equilibrium is shifted
more towards E and that Na+ binds with a higher affinity relative to hWT. In addition,
equilibrium-binding measurements using static fluorescence were performed in the
temperature range from 5 to 40 oC to investigate the thermodynamic signatures of Na+
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binding. Under all the conditions tested, hm145-150 has a higher binding affinity
compared to the hWT. Moreover, van’t Hoff plot of Na+ binding to hm145-150 shows a
linear relationship between log K versus T-1 where K is the apparent Na+ binding affinity
and T is the absolute temperature in Kelvin (Figure 4.8). Lack of curvature in the van’t
Hoff plot indicates that unlike the hwt enzyme, no heat capacity change is associated with
Na+ binding for this hm145-150 (1).

Figure 4.5 Kinetic traces of Na+ binding to hm145-150 in the 0–250-ms time scale.
Notice how the binding of Na+ obeys a two-step mechanism, with a fast phase completed
within the dead time (<0.5 ms) of the spectrometer, followed by a single-exponential
slow phase. Shown are the traces obtained at 0 (red circles), 3.125 (green circles), 25
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(blue circles), and 100 (cyan circles) mM Na+. Experimental conditions were 50 nM
thrombin, 50mMTris, 0.1% PEG, pH 8.0, at 15 °C. Continuous lines were drawn using
the expression a{1-exp(-kobst)}+ b with best-fit parameter values: red circles, a = 0.000 ±
0.000 V, kobs = 0.0 ± 0.0 s-1, b = 8.15 ± 0.011 V ; green circles, a = 0.0414 ± 0.0001 V,
kobs = 60.7 ± 15.1 s-1, b =8.393 ±0.001 V ; blue circles, a =0.0714 ±0.0002 V, kobs =
56.3± 6.4 s-1, b =8.647 ± 0.012 V ; cyan circles, a =0.0645 ± 0.001V, kobs =45.79 ± 5.6
s-1, b =8.5825 ± 0.0024 V ;

Figure 4.6 Na+ binding to hm145-150.

Binding isotherm obtained from total

fluorescence change and amplitude of fast phase. Note how the contribution of the slow
phase, which represents the E* to E transition is negligible. KAapp~KA=288 M-1
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Figure 4.7 van’t Hoff plot Na+ binding to hm145-150. Continuous line was drawn with
best-fit parameter values of ∆H= -17.43 kcal/mol, ∆S= -49.48 kcal/mol.K and ∆Cp= 0.0

To gain further insight into the molecular origins of the Na+ effects in hm145-150, crystal
structures of the mutant were solved in the presence and absence of Na+. In hwt
thrombin, there are subtle but important structural differences between the E and E: Na+
forms. These include (i) an ion-pair between Arg187 and Asp222 that stabilizes the Na+
binding site, (ii) the rotation of the Asp 189 in the primary specificity pocket, (iii) Hbonding of catalytic Ser195 and His57 and (iv) the architecture of the water channel that
spans from the Na+ site to the active site. In hm145-150 structures, these differences
between E and E: Na+ forms are not observed and both structures are similar to the E:
Na+ form of hWT. Most notably, the entire autolysis loop was defined, and unlike hWT,
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E and E: Na+ structures are basically identical. These structural characterizations gives a
plausible rationale for the observed catalytic properties, high Na+ affinity and lack of heat
capacity change associated with Na+ binding.

Figure 4.8 Alignment of the Crystal Structures of hm145-150 in the presence and absence of

Na+.

Na+-free and Na+-bound forms of hm145-150 are practically identical and are similar to Na+-bound form
of hWT [rmsd = 0.257 Å].

What is the molecular mechanism responsible for the remarkable involvement of this
loop in thrombin allostery? Structural and thermodynamic analysis may hold a key to this
answer. When the first crystal structures of human thrombin were solved, it was
hypothesized that the main function of the autolysis loop was to restrict access to the
active site cleft, endowing thrombin and other clotting factors that have longer loops with
relatively narrow substrate specificity. However, data emerging from this thesis indicate
53

this loop is critical in allostery as well. In many human thrombin structures, the autolysis
loop is either not defined due to poor electron density or it assumes different
conformations depending on crystallization conditions, demonstrating an inherently
flexible region. However, Na+ and other effector binding have been shown to rigidify and
stabilize this loop, thereby reducing exposure to proteolysis cleavage (12). Therefore, the
flexibility of the human autolysis reduces the affinity of Na+ due to an entropic cost
associated with its stabilization by Na+.

However, amino acid composition analysis of the autolysis loop in murine thrombin
indicates that this loop has a lower flexibility tendency due in part to the replacement of
two Gly residues with Ile. Indeed, intra-molecular interactions within this loop stabilize it
and as a result it is almost always well defined in crystal structures. A stable autolysis
loop in murine thrombin has been observed in structures whether free or bound to
different ligands (13, 14). Similar evidence came from the structural characterization of
hm145-150 that shows that amino acid composition of the autolysis loop can stabilize the
loop through intra loop interaction irrespective of Na+.

Revealing the mechanism of the molecular mimicry of Na+ activation in murine thrombin
and its engineering in human thrombin has great potential for understanding other
mechanism of type II M+ activation. The knowledge gained in these studies can facilitate
the rational redesign and engineering of more proficient proteases.
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CHAPTER V
Discovery of E* in other vitamin K dependent
clotting factors
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Kinetic and structural studies of the mechanism of Na+ binding to thrombin demonstrate
that the Na+ -free form (slow form) of thrombin exists in dynamic equilibrium between
two conformations E* and E (1-4). E is the active conformation of the enzyme
responsible for the catalytic activity of the enzyme in the absence of Na+ (5). However,
E* is an inactive conformation which is unable to interact with either Na+ or substrates
and is structurally distinct from the active forms (E and E:Na+).

The structural features of E* are not unique to thrombin. The collapse of the 215-217 βstrand into the active site while still maintaining an intact Ile-16 – Asp-194 has been
observed in the structures of several members of the trypsin-like serine protease (6). A
plausible hypothesis resulting from the widespread observation of inactive conformations
of trypsins is that the E*--E equilibrium is a universal property of a plastic trypsin fold
that optimizes activity and specificity after the occurrence of zymogen activation. To
begin to test this hypothesis, we investigate the existence of E* in all vitamin K dependent clotting factors. Here we report that like thrombin and meizo-thrombin desF1,
E* exists in equilibrium with E in Factor Xa, Factor IXa and activated protein C.

MATERIALS AND METHODS
Expression, purification and activation of human α-thrombin (thrombin) were performed
as described elsewhere (7, 8). Gla-domainless activated protein C (GDPC) was expressed
using a HPC4-modified pRc/RSVvector (a gift from Dr. A. Rezaie) using baby hamster
kidney cell line. Purification and activation were done as described in (9). Human Factor
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Xa (FXa) and human Factor IXa (FIXa) were obtained from Hematologic Technologies
Inc (Essex Junction, VT) while Gla-domainless Factor VIIa (GDFVIIa) was obtained
from Enzyme Research Laboratories Inc (South Bend, IN).

Intrinsic protein fluorescence was used to study the kinetic mechanism of Na+ binding to
FXa, FIXa, aGDPC and GDFVIIa in an Applied Photophysics SX20 stopped flow
spectrophotometer, using an excitation wavelength of 283 nm and a 305 nm cutoff filter
as reported in (1,4) with one important modification. Due to the interaction and inhibitory
effects of quaternary ammonium compounds with the vitamin K dependent clotting
factors (10), choline chloride could not be used as an inert ion for maintaining a constant
ionic strength as previously done for thrombin. Therefore, samples of each clotting factor
at a final concentration of 100 nM in 50 mM Tris-HCl and 0.1 % PEG, pH 8 at 15 oC was
mixed in 1:1 ratio with the same buffer containing increasing concentration of NaCl. To
check and ensure that nonspecific ionic effects are not affecting our results, Na+ binding
to human thrombin was repeated without maintaining a constant ionic strength and results
obtained were similar to the previously published data.

The fluorescence change accompanying Na+ binding is characterized by a two-step
binding mechanism, an initial fast phase that is too rapid to be resolved within the dead
time of the instrument and a single exponential slow phase whose observed rate constant
(kobs) decreases hyperbolically with increasing concentration of Na+ (see “Results”). The
initial fast phase shows an increase in fluorescence for FIIa, FXa, FIXa and GDFVIIa but
not for GDaPC where it shows a fluorescence quenching. The total change in
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fluorescence, F, calculated from the sum of the amplitudes of the slow and fast phases is
therefore expected to decrease for GDaPC accordingly. The value of F as a function of
Na+ was fit according to Equation 1 (11)

(F + F K [Na ])
F=
(1+ K [Na ])
+

0

1

app

Equation 1

+

app

! F0 and F1 are the values of F in the absence and under saturating [Na+] and Kapp is
where
the apparent equilibrium association constant for Na+ binding. However, due to the small
fluorescence change observed for Na+ binding to GDFVIIa (Figue 5.1e), its Kapp could
not be obtained with confidence from data analysis using equation 1.As previously
described for human thrombin (1), the simplest kinetic scheme accounting for the twostep mechanism of Na+ binding to each clotting factor is

k

1!
!!!
!"
#!!!!!

E*

k %1

KA

E $ E : Na +
Scheme 1

where the free enzyme exists in dynamic equilibrium between two forms, E* and E, that
interconvert with kinetic rate constants k1 and k-1. However, only E can interact with Na+
with an equilibrium intrinsic association constant KA to generate E:Na+, which results in
the fast phase. The slow phase is the result of the inter-conversion between E* and E
with a observed rate constant, kobs given by

kobs = k 1+ k!1

1
1 + K A [ Na + ]

Equation 2
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According to scheme 1 the value of kobs is expected to decrease with increasing [Na+]
from (k1+k-1) to k1 when [Na+] increases from 0 to ∞. Analysis of kobs according to
equation 2 yields the rates of conversion of k1and k-1, as well as KA. There is a
relationship between the apparent equilibrium association constant Kapp from equation 1
and KA because of the presence of E* and E,

K app =

KA
K
= A
k
1+ "1 1+ r
k1

Equation 3

where the parameter r=[E*]/[E] measures the population of E* relative to E (Table 1).

!

RESULTS
The stopped flow fluorescence measurements for Na+ binding to FXa, GDaPC and FIXa
clearly reveals a two step binding mechanism as previously shown for thrombin and
meizo-thrombin desF1 (Figure 5.1), thereby indicating similar molecular conformational
changes. A rapid fast phase that occurs within the dead time of the instrument is followed
by a single exponential slow phase whose kobs decreases hyperbolically with increasing
[Na+] (Figure 5.2). The kobs dependence on [Na+] is consistent with the mechanism shown
in scheme 1 and Equation 3. This supports the conclusion that, like thrombin, FXa,
GDaPC and FIXa exist in equilibrium between two inter-converting conformations, E*
and E where only E can interact with Na+ giving rise to the fast phase. The observed slow
phase is due to the inter-conversion between E* and E that occurs on the time scale of
milliseconds while the fast phase occurs on microsecond time scale.
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The total fluorescence change accompanying Na+ binding is obtained from the sum of the
amplitudes of the slow and fast phases and it increases hyperbolically with increasing
[Na+] (Figure 5.3) and equation 1. Analysis of Na+ binding curves enables the
determination of Kapp while the analysis of kobs as a function of [Na+] gives a direct
measurement of KA, k1 and k-1 using equation 2 (Figure 2 and Table 1).

It is of interest to note that of all the clotting factors, only GDaPC shows a decrease in
fluorescence due to Na+ binding (fast phase) preceding an increase in fluorescence in the
E* to E conversion. This observation was totally missed when using steady state
fluorescence to monitor monovalent cation binding and could account in part for the
lower %F change compared to thrombin and FXa. Na+ binding to FXa shows more
significant fluorescent change compared to the thrombin although it has fewer number of
tryptophan residues. Increase in fluorescence change when some tryptophan residues
where mutated in thrombin have also been observed (1). Because of the presence of
several tryptophan residues which are distributed throughout the protease molecule, the
changes in fluorescence induced by Na+ implies these conformational transitions are
global effects as was convincingly demonstrated in thrombin through systematic
replacements of each tryptophan residue (1).

DISCUSSION
The results presented in this study complements the investigation of the molecular
mechanisms of Na+ binding to all vitamin K dependent clotting enzymes, and
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demonstrates the existence of E*, E and E: Na+ in FIXa, FXa and GDaPC. Using steady
state measurements of intrinsic fluoresce and kinetic effects linked to Na+ binding,
previous studies have shown the presence of E and E:Na+. This study revealed for the
first time, that E is indeed in dynamic equilibrium with E*. The discovery of E* in the
vitamin K dependent clotting enzymes have mechanistic significance in understanding
the allosteric pathways, linkage effects of cations and macromolecular cofactors as well
as rationalize the effects of mutagenesis studies linked to Na+. For instance, it has been
demonstrated that the Na+ and Ca2+ sites on the protease domains of FVIIa, FIXa, FXa
and aPC are thermodynamically linked, but the molecular basis of this observation is
unknown. The presence of E* may explain this mechanism, for binding of Ca2+ on E will
shift the equilibrium away from E* (12) resulting in an increase in Kapp. Secondly, the
presence of E* may explain the drastic catalytic properties of some mutants in the
absence of Na+, Ca2+ and cofactors.

Like thrombin, activated protein C is involved in multiple distinct functions in the
anticoagulant and cytoprotective protein C pathways. Understanding the intrinsic
molecular mechanisms may aid in dissociating its functions through rational protein
engineering. Activated protein C utilizes both Na+ and Ca2+ for optimal catalytic activity
(13). In vivo, efficient inactivation of Factor Va, requires both Na+ and Ca2+ and
mutations that disrupts the Na+ allostery are significantly compromised in Ca2+ binding
and activity towards Factor Va (13). Although, the Na+ site and the Ca2+ are
thermodynamically, only the former is linked to the active site (14).
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Factor IXa and Factor Xa function in the tenase and prothrombinase complexes
respectively (15) and in this context, it has been shown Na+ is not required neither for the
assembly nor for the catalytic enhancement of these membrane complexes (16, 17).
However, Na+ in conjunction with Ca2+ are needed for the optimal amidolytic properties
of each of these enzymes when free in solution (18, 19). Therefore, the either the relevant
in vivo complexes utilitize novel pathways to enhance the catalytic properties of these
enzymes or they simply replace the effects of Na+. Several mutagenesis studies seem to
support the latter in that in both FIXa and FXa Y225P mutants whose Na+ machinery are
severely weakened, the catalytic properties are significantly compromised in the presence
or absence of Ca2+when free in solution. However, when these mutants are assembled in
the tenase and prothrombinase complexes, the Km but not the kcat effect for both small
chromogenic and macromolecular substrates are fully restored to that of the wild type
(17, 18). In addition, both Na+ and Ca2+ ions are required for the effective inhibition of
wild type FIXa and FXa and here too, their Y225P mutants are significant compromised
for inhibition by antithrombin. These data seem to support that, in vivo, because of the
roles of Ca2+and macromolecular cofactors in mediating the interaction of enzymes and
substrates on the surfaces of membranes and their linkage to the Na+ site, the effect of
Na+ is drastically reduced in wild type FXa and FIXa when incorporated in the tenase and
prothombinase complexes respectively. This is reminiscent of role of Na+ in the presence
of thrombomodulin. Not only do these cofactors provide the beneficial effects of Na+
allostery, they can increase their effects through protein-protein and protein-membrane
interactions.
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FIGURE 5. 1. Kinetic traces of Na+ binding to vitamin K dependent clotting factors in the
0–250-ms time scale. Notice how the binding of Na+ obeys a two-step mechanism, with a fast
phase completed within the dead time (<0.5 ms) of the spectrometer, followed by a singleexponential slow phase. The kobs for the slow phase decreases with increasing [Na+] (see also Fig.
2), as is evident from the plot.
Human α-thrombin. Shown are the traces obtained at 0 (red circles), 3.125 (green circles), 25
(blue circles), and 200 (magenta circles) mM Na+.

Experimental conditions were 100 nM

thrombin, 50mMTris, 0.1% PEG, pH 8.0, at 15 °C. Continuous lines were drawn using the
expression a {1-exp (-kobst)}+ b with best-fit parameter values: red circles, a = 0.000 ± 0.000 V,
kobs = 0.0 ± 0.0 s-1, b = 8.239 ± 0.016 V; green circles, a = 0.000 ± 0.000 V, kobs =0.0 ± 0.0 s-1, b
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=8.470 ±0.001 V; blue circles, a =0.1754 ±0.0099 V, kobs = 120.0± 9.5 s-1, b =9.1174 ± 0.0012 V;
magenta circles, a =0.3921 ± 0.0013V, kobs =95.6 ± 4.3 s-1, b =9.7321 ± 0.0025 V ;

Factor Xa. Shown are the traces obtained at 0 (red circles), 20 (green circles), 120 (blue circles),
and 400 (magenta circles) mM Na+. Experimental conditions were 100 nM FXa, 50mMTris,
0.1% PEG, pH 8.0, at 15 °C. Continuous lines were drawn using the expression a {1-exp (kobst)}+ b with best-fit parameter values: red circles, a = 0.000 ± 0.000 V, kobs = 0.0 ± 0.0 s-1, b =
8.1120 ±0.0001 V; green circles, a = 0.000 ± 0.000 V, kobs =0.0 ± 0.0 s-1, b =8.6010 ±0.0019 V;
blue circles; a =0.2613 ± 0.0017 V, kobs = 64.1 ± 3.9 s-1, b = 9.1297±0.0012 V magenta circles, a
=0.4876 ±0.0011 V, kobs = 60.3 ± 1.2s-1, b = 9.4274 ± 0.0015 V ;
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GDaPC. Shown are the traces obtained at 0 (red circles), 25 (green circles) and 300 (blue
circles) mM Na+. Experimental conditions were 100 nM GDaPC, 50mMTris, 0.1% PEG, pH 8.0,
at 15 °C. Continuous lines were drawn using the expression a {1-exp (-kobst)}+ b with best-fit
parameter values red circles, a = 0.000 ± 0.000 V, kobs = 0.0 ± 0.0 s-1, b = 8.4850 ± 0.0013 V;
green circles, a =0.1617 ±0.0011 V, kobs = 30.7 ± 0.9 s-1, b = 8.3393± V; blue circles, a =0.4578±
0.0012V, kobs =26.5 ± 0.4 s-1, b = 8.1492± 0.0011 V
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FIXa. Shown are the traces obtained at 0 (red circles), 100 (green circles) and 400 (blue circles)
mM Na+. Experimental conditions were 100 nM FIXa, 50mMTris, 0.1% PEG, pH 8.0, at 15 °C.
Continuous lines were drawn using the expression a {1-exp (-kobst)}+ b with best-fit parameter
values red circles, a = 0.000 ± 0.000 V, kobs = 0.0 ± 0.0 s-1, b = 8.2030 ± 0.0012 V; green circles,
a =0.000 ±0.0000 V, kobs = 0.0 ± 0.0 s-1, b = 8.3530± V; blue circles, a =0.1031± 0.0009V, kobs
=31.6 ± 0.9 s-1, b = 8.4165± 0.0018 V

69

GDFVIIa. Shown are the traces obtained at 0 (red circles) and 400 (green circles) mM Na+.
Experimental conditions were 100 nM GDFVIIa, 50mMTris, 0.1% PEG, pH 8.0, at 15 °C.
Continuous lines were drawn using the expression a {1-exp (-kobst)}+ b with best-fit parameter
values red circles, a = 0.000 ± 0.000 V, kobs = 0.0 ± 0.0 s-1, b = 8.1340 ± 0.001 V; green circles, a
=0.000 ±0.0000 V, kobs = 0.0 ± 0.0 s-1, b = 8.2230± 0.0001V
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FIGURE 2. Values of kobs for the slow phase of fluorescence increase due to Na+ binding to
clotting factors (see Fig. 1) as a function of [Na+]. Shown are the results pertaining to FIIa (red
circles), FXa (green circles), GDaPC (blue circles) and FIXa (magenta circles). Continuous lines
were drawn according to Equation 2 under “Materials and Methods” with best-fit parameter
values listed in Table 1. Continuous lines were drawn according to Equation 3 under “Materials
and Methods” with best-fit parameter values listed in Table 1.
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FIGURE 5.3. Na+ binding curves of clotting factors obtained from the total change in intrinsic
fluorescence measured as the sum of the amplitudes of the fast and slow phases determined by
stopped-flow kinetics (see Fig. 1). Shown are the results pertaining to FIIa (red circles), Fxa
(green circles), GDaPC (blue circles) and FIXa (magenta circles). Continuous lines were drawn
according to Equation 2 under “Materials and Methods” with best-fit parameter values listed in
Table 1.
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Clotting Factor

F0

F1

ΔF/F0

Kapp

KA

k1

k-1

M-1

M-1

s-1

s-1

r

V

V

%

FIIa

8.20 ± 0.05

9.39 ± 0.03

14.5

119±12

162 ± 20

89±2

85±9

0.95

FXa

8.23 ± 0.05

10.47 ± 0.16

27.2

10 ± 2

16 ± 4

45± 4

68 ± 12

1.49

GDaPC

8.15 ± 0.03

8.66 ± 0.02

6.1

59 ± 3

116 ± 15

25 ± 1

24 ± 3

0.95

FIXa

8.21 ± 0.01

8.51± 0.03

3.6

~ 0.8 ± 0.1

-

-

-

-

GDFVIIa

8.13 ± 0.02

8.22 ± 0.01

1.1

-

-

-

-

-

TABLE 5.1 Fluorescence and binding parameters for Na+ binding to the Vitamin K
dependent clotting factors. The parameters F0, F1 and ΔF=F1-F0 and Kapp were derived from
analysis of the data in Figure 3 using Equation 1 under “Materials and Methods”. The value of
KA, k1,k-1 and r=k-1/k1 were derived from analysis of the data from figure 2 using Equation 2 .
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CHAPTER VI
Summary, Discussion & Future Directions
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Data from this thesis as well as from recent kinetic and structural observations on
thrombin and other S1 proteases support a considerable and unexpected plasticity of the
trypsin fold (1). Through protein conformational dynamics, the protease can inter-convert
between inactive E* and active E forms. E* features a collapse of the 215-217 β-strand
into the active site, a disruption of the oxyanion hole due to a flip of the peptide bond
between Glu192 and Gly193, and abrogation of the Na+ site (2, 3). Consequently, E* is
basically unable to interact with either substrate or bind Na+.

The structural differences between E and E:Na+ are subtle, but the E* structure differs
significantly from both, as such the E* to E transition involves unprecedented
conformational changes (4). More importantly however, an intact ion-pair between Ile16
and Asp194 is still maintained in all the structures of E*, suggesting that this
conformation is not equivalent to the zymogen form, which is characterized by a broken
Ile16-Asp194 ion-pair and lack of a collapse of the 215-217 β-strand (5, 6). Furthermore,
stopped-flow experiments show that the E* to E transition takes place on a time scale <10
msec compared to the zymogen – protease conversion that occurs on a longer (100-1000
msec) time scale (7, 8).

E* is not unique to the vitamin K-dependent clotting factors, however. Structural
features of E* like collapse of the 215-217 β-strand into the active site or the disruption
of the oxyanion hole have also been observed in other structures of serine proteases such
as tryptases and complement factors (1). These observations support E* as an inactive
form that is in allosteric equilibrium with the active form E of the protease. Serine
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proteases are therefore allosteric enzymes whose activity can be fine tuned by modulating
the E*-E equilibrium. Allostery is more often discussed in multimeric proteins like
hemoglobin where large scale conformational transitions are usually evident (9). The
structural plasticity demonstrated in monomeric proteins like serine proteases supports
the idea that allostery is an intrinsic property of all dynamic proteins closely intertwined
with catalysis (10). As shown in this thesis work, conformational plasticity is an integral
part of protease function, regulation and substrate specificity.

What is the physiological advantage of the E*-E equilibrium? Depending on the activity
requirement of each protease, the E* to E equilibrium can be set to optimize the function
of that protease. For low activity proteases, the equilibrium favors E* while the reverse is
true for high activity protease.

FUTURE DIRECTIONS
I.

THROMBIN AND ANTICOAGULANT THERAPY

Safe and effective anticoagulants are needed for treatment and prevention of thrombotic
disorders such as venous thrombosis and acute myocardial infarction (11). Current
anticoagulant therapy is dominated by heparinoids, which are involved in antithrombin
inhibition of thrombin and factor Xa; and warfarin, a generic inhibitor of the synthesis of
all vitamin K -dependent clotting factors. Amongst the limitation of heparin and warfarin
are a narrow therapeutic window and an unpredictable dose-response profile (12). Direct
thrombin inhibitors like hiruden and bivalirudin are highly selective for thrombin, yet do
no have a superior therapeutic efficacy and safety compared with low molecular weight
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or even unfractionated heparins. Therefore new strategies are needed to generate more
efficacious anticoagulants (12).

Because of its paradoxical roles in the procoagulant and anticoagulant pathways,
thrombin mutants with selective specificity toward the anticoagulant protein C pathway
have been rationally engineered and show potent and safe anticoagulant and
antithrombotic effects in vivo. α-Thrombin mutants, E217K and W215A/E217A that
show anticoagulant and antithrombotic effects in non-human primates both exhibit some
structural features of E* like partial collapse of the 215-217 β-strand and disruption of
the oxyanion hole (13-15). Thus stabilization of E* through mutagenesis or binding of a
small molecule can provide an elegant regulatory control that can fine tune specificity
along a particular pathway (3). The presence of E* in thrombin have significance
mechanistic importance in generating a completely anticoagulant thrombin with no or
minimal effect on fibrinogen and PAR1. Because of the collapsed active site, a mutant
completely stabilized in E* will not interact with substrates or bind inhibitors. However,
when such mutant interacts with TM-protein C complex, it can regain its ability to
activate protein C. Stabilization of E* provides a novel strategy for generating
anticoagulant thrombins and it can be pursued through mutagenesis or binding by small
molecules identified through high throughput screening techniques.

II.

E* in other proteolytic enzymes

In this thesis project, we have investigated the presence of inactive E* conformations in
vitamin K- dependent clotting factors using Na+ as a probe to perturb the E* to E
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equilibrium. However, for proteolytic enzymes that do not interact or interact weakly
with Na+, this strategy cannot be used. Therefore, specific active site or exosite probes
should be generated to investigate whether E*-like conformations are present in solution.
In addition, to detect structural features of E*, crystallographic studies should be pursued
in the absence of salts or inhibitors to prevent any allosteric transitions caused by these
effectors. Alternatively, proteolytic enzymes that are amenable to NMR studies,
structural and kinetic characterization of E* can be performed simultaneously using
specific experiments based on CPMG relaxation dispersion that have been develop to
investigate the low-populated transiently-formed conformations in proteins. These
techniques can be very useful for instance to investigate changes in dynamics of the E* to
E transition in the presence of effectors.

III.

Role of the autolysis loop in S1 proteases
Sequence comparison of S1 serine proteases shows a lack of conservation in amino acid
composition and length in the 145-150-loop region. However, this loop is strategically
located between the 186- and 220 loops (the Na+ binding site in some cases), the active
site and exosite I/Ca2+ binding site. In many enzymes with longer loops, this region is
highly flexible and susceptible to proteolysis, and in crystal structures it is either not
defined or assumes different conformations depending on the crystallization conditions.
Therefore, it became very difficult to allocate a definite function and it was proposed that
the main function of this loop is to restrict access to the active site cleft. However, studies
from our lab and others as well as data from this project shows that composition of the
autolysis loop plays a major role in protease allostery and specificity. For instance,
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deletion of the nine residues from human thrombin have stabilized that E* conformation
whilst substitution of this loop with it murine counterpart resulted not only in a high
activity human enzyme in the absence of Na+, it generated a thrombin mutant with a
higher Na+ binding affinity compared to the WT (Chapters 3 & 4). Taken together, these
results indicate that this loop is at the heart of protease allostery due to its strategic
location, and can be used to modulate specificity by optimizing its sequence composition
and length. Therefore, protease engineering efforts focusing on this loop in other trypsinlike serine proteases have the potential to modulate activity and generate more proficient
enzymes especially for biological or industrial purposes.
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